


RESEARCH ARTICLE

Symptomatic spinal metastasis: A systematic literature review of the preoperative prognostic factors for survival, neurological, functional and quality of life in surgically treated patients and methodological recommendations for prognostic studies

Anick Nater¹, Allan R. Martin¹, Arjun Sahgal², David Choi³, Michael G. Fehlings^{1,4*}

1 Department of Surgery, Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada, **2** Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Canada, **3** Department of Neurosurgery, The National Hospital for Neurology and Neurosurgery, and Institute of Neurology, University College London, London, United Kingdom, **4** Department of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

* michael.fehlings@uhn.ca


 OPEN ACCESS

Citation: Nater A, Martin AR, Sahgal A, Choi D, Fehlings MG (2017) Symptomatic spinal metastasis: A systematic literature review of the preoperative prognostic factors for survival, neurological, functional and quality of life in surgically treated patients and methodological recommendations for prognostic studies. PLoS ONE 12(2): e0171507. doi:10.1371/journal.pone.0171507

Editor: Shian-Ying Sung, Taipei Medical University, TAIWAN

Received: October 13, 2016

Accepted: January 3, 2017

Published: February 22, 2017

Copyright: © 2017 Nater et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: Dr. Fehlings is supported by the Gerry and Tootsie Halbert Chair in Neural Repair and Regeneration and the DeZwirek Family Foundation.

Competing interests: I have read the journal's policy and the authors of this manuscript have the

Abstract

Purpose

While several clinical prediction rules (CPRs) of survival exist for patients with symptomatic spinal metastasis (SSM), these have variable prognostic ability and there is no recognized CPR for health related quality of life (HRQoL). We undertook a critical appraisal of the literature to identify key preoperative prognostic factors of clinical outcomes in patients with SSM who were treated surgically. The results of this study could be used to modify existing or develop new CPRs.

Methods

Seven electronic databases were searched (1990–2015), without language restriction, to identify studies that performed multivariate analysis of preoperative predictors of survival, neurological, functional and HRQoL outcomes in surgical patients with SSM. Individual studies were assessed for class of evidence. The strength of the overall body of evidence was evaluated using GRADE for each predictor.

Results

Among 4,818 unique citations, 17 were included; all were in English, rated Class III and focused on survival, revealing a total of 46 predictors. The strength of the overall body of evidence was *very low* for 39 and *low* for 7 predictors. Due to considerable heterogeneity in patient samples and prognostic factors investigated as well as several methodological issues, our results had a moderately high risk of bias and were difficult to interpret.

following competing interests: Dr. Michael Fehlings has consulting agreements with Zimmer Biomet, InVivo Therapeutics, and Pfizer. Dr. Arjun Saghal has given educational seminars with Medtronic, Elekta AB, Accuray Inc., and Varian medical systems; acted in a consulting or advisory role with Varian medical systems, Hoffmann-La Roche Limited; has been awarded research grants from Elekta AB; has received travel accommodations and expenses from Medtronic, Elekta and Varian; and belongs to the Elekta MR Linac Research Consortium. There are no patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.

Abbreviations: ASIA, American Spinal Injury Association; CCIS, Charlson comorbidity index score; CPRs, clinical prediction rules; ECOG, Eastern Cooperative Oncology Group; EQ-5D, EuroQol 5 dimensions; FIM, functional independence measure; GRADE, Grading of Recommendation Assessment, Development and Evaluation; HCC, hepatocellular carcinoma; HRQoL, health related quality of life; KPS, Karnofsky performance status; MM, multiple myeloma; MRC, Medical Research Council; NSCLC, non-small cell lung carcinoma; ODI, Oswestry Disability Index; PH, proportional hazards; PHA, proportional hazards assumption; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, International Prospective Register of Systematic Reviews; SF-36, short form health survey; SSM, symptomatic spinal metastasis.

Conclusions

The quality of evidence for predictors of survival was, at best, *low*. We failed to identify studies that evaluated preoperative prognostic factors for neurological, functional, or HRQoL outcomes in surgical patients with SSM. We formulated methodological recommendations for prognostic studies to promote acquiring high-quality evidence to better estimate predictor effect sizes to improve patient education, surgical decision-making and development of CPRs.

Introduction

Symptomatic spinal metastasis (SSM) afflicts up to 10% of cancer patients[1–3], of which approximately 10% are surgically managed.[4] Given that over 14 million Americans lived with a diagnosis of cancer in 2014 and almost 19 million are expected to do so by 2024[5], the number of cancer survivors expected to undergo surgery for SSM will increase by approximately 36% over the next 10 years.

Since the randomized controlled trial conducted by Patchell et al.[6] showing that surgery followed by radiotherapy provided superior neurologic outcomes compared to radiotherapy alone in patients suffering from a single cervical or thoracic SSM with a life expectancy of ≥ 3 months, this life expectancy threshold has been widely adopted in decision-making for surgical treatment.[7–9] However, clinicians and surgeons tend to estimate survival in patients with advanced cancer inaccurately.[10–13] Also, although several studies reported that surgical intervention improved health related quality of life (HRQoL)[6, 9, 14–20], SSM treated with surgery is the most costly skeletal-related event in patients with cancer.[21]

Clinical prediction rules (CPRs), which combine various clinical factors from an individual with a given health state and provide an estimate of the risk of experiencing a specific endpoint within a certain period[22], may allow physicians to make more precise clinical estimates and thus assist therapeutic decision-making and counselling.[22, 23] Although several CPRs of survival have been elaborated, we are not aware of any CPR for HRQoL for SSM patients. Also, current CPRs of survival have variable prognostic ability.[24–26] This may be due to differences between patient samples that were used to generate and conduct prognostic value assessment. For instance, Bartels et al.[27] created a CPR of survival based on a cohort of patients who received radiotherapy. In their most recent external validation study[28], misspecification of their model was attributed to the surgical patient subgroup.

The majority of published series assessed preoperative predictors of survival rather than HRQoL. We conducted a systematic review to ascertain the preoperative prognostic factors for 1) survival, 2) neurologic status, 3) functional status, and 4) HRQoL in surgical SSM patients. We also appraised the methodology and reporting of prognostic studies that met our eligibility criteria. The results of this study could not only be used to modify existing CPRs of survival to improve their prognostic value, but also to improve the theoretical framework to develop new CPRs for survival and HRQoL outcomes specific to surgical SSM patients.

Methods

This systematic review and best-evidence synthesis was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[29]. In compliance with the guidelines, our systematic review protocol was

registered with the International Prospective Register of Systematic Reviews (PROSPERO)[30] on June 24th, 2015 and was last updated on July 12th, 2016 (registration number CRD42015023831).

Literature search

In adult patients who underwent surgery for SSM, we sought to answer the following four key questions (KQs): What are the preoperative clinical factors associated with postoperative (1) survival; (2) neurologic status, such as muscle power on the Medical Research Council (MRC) scale for testing muscle strength, neurologic outcome measures (e.g. American Spinal Injury Association (ASIA) or Frankel grade) or autonomic functions (bladder / bowel control); (3) functional status, in terms of ambulatory status, functional outcome measures, such as functional independence measure (FIM), Barthel index, Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (KPS); and (4) HRQoL, in terms of score on any HRQoL measure, such as short form health survey (SF-36), EuroQol 5 dimensions (EQ-5D) or Oswestry Disability Index (ODI)?

The electronic databases MEDLINE, MEDLINE in Process, Embase, Web of Science, CINAHL, Cochrane Central Register of Controlled Trials, and Scopus were systematically searched for studies performed in humans from January 1, 1990 to December 31, 2015 with no language restrictions applied. The search strategies were developed in consultation with information specialists at the University Health Network Health Sciences Libraries. [S1 Table](#) presents our complete search strategies. The reference lists of studies meeting the eligibility criteria and relevant review papers were manually screened for additional studies.

Eligibility criteria

Citations were screened for eligibility by following *a priori* determined inclusion and exclusion criteria ([Table 1](#)). Original studies with an identifiable surgical treatment arm or surgical cohort of at least 30 patients, who underwent *de novo* spinal surgery for a single symptomatic metastatic spinal lesion, with a postoperative follow-up of at least 6 months, published in peer-reviewed journals included in Ulrichsweb[31] at the time of publication, describing and reporting both the preoperative prognostic clinical factors assessed and the univariate and multivariate analyses conducted, were considered for inclusion. Studies that included surgical/postoperative predictors in their multivariate analyses, patients < 18 years old, patients operated for recurrent SSM or primary spinal tumor were excluded.

Screening and selection

All duplicates were removed using EndNote X4 followed by manual elimination. Two authors (AN and ARM) independently (1) screened the titles and abstracts to identify potential eligible studies to undergo full-text assessment and then (2) reviewed the selected full-text articles for final inclusion. Discrepancies between the two reviewers were resolved by consensus agreement; persisting disagreements were settled by consulting the senior author (MGF).

Data extraction and synthesis

The following data were extracted by AN and then checked by ARM: 1) first author and publication date; 2) publication language; 3) study design; 4) purpose; 5) patient sample and characteristics, with relevant inclusion and exclusion criteria; 6) preoperative predictors 7) outcome assessed; 8) postoperative follow-up characteristics, including length, rate, and information about how missing data were handled; 9) methodology, including details related to predictors'

Table 1. Inclusion and exclusion criteria.

	Inclusion	Exclusion
Patient	De novo surgically treated adults MESCC patients included in a surgical series of at least 30 patients published from January 1, 1990 to December 31, 2015	<ul style="list-style-type: none"> • MESCC due to trauma, infection, stenosis, degenerative changes, primary CNS or vertebral tumor • Pediatric (< 18 years)
Intervention	Surgical treatment ¹ performed for at least one of the following indications: <ul style="list-style-type: none"> • Intractable pain resulting from a symptomatic MESCC lesion • Spinal instability: imminent or overt • Onset or progression of neurologic deficits, i.e. sensorimotor or autonomic 	<ul style="list-style-type: none"> • All non-surgical treatments (hormonotherapy, immunotherapy, chemotherapy, corticosteroid, and radiotherapy, including conventional external beam radiotherapy, intensity-modulated radiotherapy, stereotactic radiosurgery / stereotactic body radiation therapy, stereotactic radiotherapy and systemic application of radioisotopes) used alone • Surgery for recurrent MESCC lesion
Study design	Original series <ul style="list-style-type: none"> • From all languages and at the time of publication, published in peer-reviewed journals between January 1, 1990 to December 31, 2015 • Prospective and retrospective studies with a follow-up of at least six months • With an identifiable surgical treatment arm or surgical cohort of at least 30 patients • Providing adequate description of pre-operative factors² • With adequate description of the (1) preoperative predictive clinical factors assessed and (2) univariate and multivariate analyses conducted • With the results of univariate and multivariate analyses clearly reported <p>Studies that used the same data were individually included as long as they satisfy our eligibility criteria</p> <p>Studies validating or examining the accuracy of existing scoring systems were included if (1) they met the eligibility criteria, (2) patient sample was different from the one used to develop the scoring system (3) and the predictive value of the preoperative clinical factors constituting the scoring system were individually assessed and clearly reported.</p>	<ul style="list-style-type: none"> • Animal or biomechanical studies • Opinions • Commentaries • Editorials • Conference proceedings • Systematic reviews • Meta-analyses • Studies that involved multivariate analysis that included surgical or postoperative factors as predictors
Outcome	<ul style="list-style-type: none"> • Survival • Neurologic outcomes <ul style="list-style-type: none"> • muscle power • sphincter dysfunction, i.e. bladder and bowel control • sexual dysfunction • ASIA or Frankel score • Functional outcomes <ul style="list-style-type: none"> • Karnofsky / ECOG performance status • Ambulatory status • Quality of life <ul style="list-style-type: none"> • Score on any given metrics or instruments assessing health related quality of life 	

¹ Spinal surgery refers to a *de novo* surgical treatment involving any open or minimally invasive spinal interventions, including vertebroplasty and kyphoplasty, to achieve partial or complete spinal decompression and/or mechanical stabilization, with or without instrumentation

² Potential pre-operative predictive factors include clinical features such as sex, age, ethnicity, body mass index (BMI), smoking status, histologic type or site of the primary tumor, biomarkers, treatment received for primary and/or spinal metastasis, performance status score and SF-36. Potential surgical predictive factors include type of surgery and extent of tumor resection, length of operation and blood loss.

ASIA: American Spinal Injury Association; **ECOG:** Eastern Cooperative Oncology Group; **MESCC:** metastatic epidural spinal cord compression

doi:10.1371/journal.pone.0171507.t001

selection, type of univariate and multivariate analyses conducted, multivariate modeling process and assumption(s) testing; and 10) univariate and multivariate estimates, including reported odds / hazard ratios and confidence intervals. Unless otherwise specified, a p -value < 0.05 was considered statistically significant.

Critical appraisal of the literature

We are not aware of any consensus regarding a standardized approach for assessing the quality of prognostic studies.

Risk of bias in individual studies

AN and ARM independently assessed the risk of bias of individual articles (Class I to IV) using the method described by Skelly et al.[32, 33] for prognostic studies (S2 Table). The final class-of-evidence rating was assigned following consensus agreement.

Risk of bias across studies: Overall quality of evidence

Once all articles were individually evaluated, the strength of the overall body of evidence with respect to each predictor was allocated using the approach developed by the Grading of Recommendation Assessment, Development and Evaluation (GRADE) Working Group.[34] The *baseline* strength of the overall body of evidence was assigned “High” if the majority of the studies were Class I or II and “Low” if the majority of the studies were Class III or IV. The strength could then be downgraded by one or two levels based on the risk of bias, consistency, directness, precision and publication bias. Alternatively, the strength could be upgraded by one or two levels if the effect was large, there was evidence of a dose response gradient or all plausible confounders would either reduce a demonstrated effect or would suggest a spurious effect when the results showed no effect. The *final* strength of the overall body of evidence for each predictor was classified as High, Moderate, Low or Very Low and expresses our confidence that the evidence reflects the true effect and the likelihood of further research to change our confidence in the latter estimate of effect (S3 Table). Overall, this method adheres to the general principles described by Hayden et al.[35] for assessing the quality of prognostic studies in systematic reviews.

Results

The search yielded 4,818 unique citations, of which the title and abstract were screened, leading to the selection of 152 articles for full-text review. Among these, a total of 135 studies were excluded for one of the following reasons: preoperative prognostic factors were not evaluated or were assessed as part of a scoring system and not evaluated individually; multivariate analysis was not conducted; multivariate analysis included surgical and/or postoperative factors as predictors; the journal was not peer-reviewed at the time of publication on Ulrichsweb[31]; surgical patients were not evaluated separately from non-surgical patients; the study included less than 30 surgical patients; spinal metastases were not distinguished from extraspinal bony metastases; patient sample included patients < 18 years of age; the study involved metastasis from primary central nervous system tumors; postoperative follow-up was less than six months. No additional studies were added after manually checking reference lists (Fig 1).

All 17 articles meeting our eligibility criteria were published in English and addressed KQ1, i.e. the preoperative clinical factors associated with survival in surgical SSM patients. There were six additional studies that examined the clinical prognostic factors of functional status (KQ3) in terms of the ability to walk[36–41] or regaining the ability to walk[37]




Fig 1. Study selection process.

doi:10.1371/journal.pone.0171507.g001

postoperatively and one study that isolated key predictors of survival (KQ1) and HRQoL (KQ4) using the postoperative EQ-5D score as the dependent variable[42]. However, these studies included surgical and/or postoperative factors in their multivariate analysis, leading to their exclusion from this review.

Survival

All 17 studies investigated the prediction of survival, pursuing one or more of the following aims: to evaluate (1) predictors of survival; (2) predictors of survival and propose a prognostic model or a scoring system to predict survival; (3) the prognostic value of parameters included in an existing scoring system that predict survival. Ten studies examined aim #1[43–52], including four that analyzed a heterogeneous population of primary tumor types[43–45, 50], one study focused on patients older than 60 years of age[46], and the remainder investigated specific primary malignancy types including breast cancer[48], hepatocellular carcinoma (HCC)[52], prostate cancer[49] or non-small cell lung cancer (NSCLC)[51] and unknown primary[47]. Four studies addressed aim #2[41, 53–55], including one that involved a heterogeneous primary tumor type[53], prostate cancer[54], lung cancer[55] or NSCLC[41]. Four studies explored aim #3[24, 52, 56, 57], with three involving heterogeneous primary tumor type[24, 56, 57] and one focused on HCC[52].

Risk of bias of individual studies

Prospective prognostic studies meeting the following criteria for a good-quality cohort study are considered Class I evidence: (1) patients were followed for sufficient periods in order that outcomes could occur, (2) follow-up rate was $\geq 80\%$, (3) patients were at similar point in the course of their disease, and (4) the study accounted for other prognostic factors (S2 Table). Although this review included three prospective studies[24, 47, 56], they were considered as Class III evidence due to violation of two of the criteria for good-quality cohort studies: follow-up period and drop-out rate were not clearly specified. The remaining 14 retrospective studies were also considered Class III due to violation of at least one of the criteria for good-quality studies.

Results of individual studies

A summary of the 17 studies is presented in Table 2. Numerous preoperative clinical factors were reported to negatively impact survival when all sites of primary tumor were considered: primary tumor type (e.g. lung, colon)[43, 45, 56], radioresistant primary tumor[50], primary tumor Tomita Grade III (modified Tomita classification[57] and original classification)[24], primary tumor Tomita Grade II and III (original classification)[53], poor prognosis of primary tumor (based of median survival < 20 months[44]), presence of visceral metastasis[24, 53, 56, 57], KPS $< 80\%$ [56, 57], presence of neurologic deficit (e.g. palsy)[43, 44], presence of non-symptomatic spinal metastasis[53, 56], incapacity to walk independently or with a walking aid[50], Charlson comorbidity index score (CCIS) ≥ 2 [50], older age[43], male sex[43], presence of pain[44], and ASIA score B or C[45]; and a score of 9–12 points on the original Tokuhashi scoring system and primary tumor Tomita Grade III (original classification)[46] in patients ≥ 60 years old.

Prognostic factors for survival varied substantially according to primary tumor types, with negative relationship as follows: breast cancer with shorter time interval from cancer diagnosis to SSM surgery, emergency hospital admission, primary tumor with poor/undifferentiated histologic grade and negative progesterone receptors[48]; HCC with low serum albumin and high lactate dehydrogenase [52]; prostate cancer with KPS 50–70%[54], Gleason score > 8

Table 2. Evidentiary table of 17 studies identifying preoperative predictive factors of survival in surgical SSM patients.

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method Univariate; Multivariate	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Aizenberg, 2012, Prospective (III)	<ul style="list-style-type: none"> • Single center • June 1993 to February 2007 • n = 51 • Unknown primary tumor • Median age: 59.9 • 16 F: 35 M 	<ul style="list-style-type: none"> • Cox PH model for both uni- and multivariate • Variables with $p < 0.15$ in univariate analysis were included in multivariate analysis and tested through a backward stepwise selection 	<p>Spinal location (cervical vs. other location)</p> <p>Frankel score (A, B, C vs. D, E)</p> <p>Extraspinal disease at presentation (present vs. absent)</p> <p>Other spine disease (present vs. absent)</p> <p>Timing of surgery, i.e. from presentation to surgery (≥ 2.6 vs. < 2.6 mo)</p> <p>Extend of resection (GTR vs. STR, surgeon's estimate at surgery)</p> <p>Lymph node involved at presentation (involved vs. not)</p> <p>Age at surgery (> 60 vs. ≤ 60 years, based on median age)</p> <p>Sex (female vs. male)</p> <p>Spinal metastatic disease as initial presentation (yes vs. no)</p> <p>Prior treatment to spinal metastasis (yes vs. no)</p>	<p>Multivariate: HR: NR, <i>cervical</i>: MS: 6.4 mo; 95% CI: 1.1–11.7; <i>other location</i>: MS: 11.8 mo; 95% CI: 4.5–19.11; $p = 0.01$</p> <p>Multivariate: HR: NR, A, B, C: MS: 2.7 mo; 95% CI: 0.6–3; D, E: MS: 11.8 mo; 95% CI: 6–17.8; $p = 0.029$</p> <p>Multivariate: HR: NR, <i>present</i>: MS: 6.4 mo; 95% CI: 2.6–10.2; <i>absent</i>: 18.1 mo; 95% CI: 10.1–26.1; $p = 0.041$</p> <p>Multivariate: HR: NR, <i>present</i>: MS: 12.7 mo; 95% CI: 0.6–24.8; <i>absent</i>: MS: 8.7 mo; 95% CI: 0–18.3; $p > 0.05$</p> <p>Multivariate: HR: NR ≥ 2.6 MS: 12.7 mo; 95% CI: 1–24.5; < 2.6 MS: 6.8 mo; 95% CI: 2.9–10.7; $p > 0.05$</p> <p>Univariate: HR: NR, <i>GTR</i>: MS: 8.1 mo; 95% CI: 0–18.5; <i>STR</i>: 6.4 mo; 95% CI: 0–13.2; $p = 0.18$</p> <p>Univariate: HR: NR, <i>involved</i>: MS: 8.1 mo; 95% CI: 0–17.2; <i>not involved</i>: 8.7 mo; 95% CI: 0–17.4; $p = 0.40$</p> <p>Univariate: HR: NR, <i>60</i>: MS: 8.7 mo; 95% CI: 0–17.6; ≤ 60 MS: 8.1 mo; 95% CI: 0–17.9; $p = 0.56$</p> <p>Univariate: HR: NR, <i>Female</i>: MS: 5.4 mo; 95% CI: 2.9–7.8; <i>Male</i>: MS: 12.8 mo; 95% CI: 2.1–23.4; $p = 0.17$</p> <p>Univariate: HR: NR, <i>yes</i>: MS: 8.7 mo; 95% CI: 1.1–16.2; <i>no</i>: MS: 8.1 mo; 95% CI: 0–25; $p = 0.82$</p> <p>Univariate: HR: NR, <i>yes</i>: MS: 6.8 mo; 95% CI: 2.8–10.8; <i>no</i>: MS: 12.8 mo; 95% CI: 1.1–24.4; $p = 0.25$</p> <p>Univariate: $p < 0.0001$, <i>Multivariate</i>: HR: 2.557; 95% CI: 1.672–3.912; $p < 0.0001$</p> <p>Univariate: $p < 0.0001$, <i>Multivariate</i>: HR: 2.355; 95% CI: 1.517–3.658; $p = 0.0001$</p> <p>Univariate: $p = 0.0058$, <i>Multivariate</i>: HR: 2.955; 95% CI: 1.341–6.512; $p = 0.0072$</p> <p>Univariate: $p = 0.9936$, <i>Multivariate</i>: HR: 1.001; 95% CI: 0.986–1.016; $p = 0.8956$</p> <p>Univariate: NR, <i>Multivariate</i>: HR: 1.070; 95% CI: 0.693–1.652; $p = 0.7611$</p> <p>Univariate: $p = 0.4813$, <i>Multivariate</i>: HR: 1.408; 95% CI: 0.954–2.078; $p = 0.0853$</p> <p>Univariate: $p = 0.0829$, <i>Multivariate</i>: HR: 0.980; 95% CI: 0.673–1.427; $p = 0.9144$</p> <p>Univariate: $p = 0.3704$, <i>Multivariate</i>: HR: 1.089; 95% CI: 0.754–1.573; $p = 0.6486$</p> <p>Univariate: $p = 0.0916$, <i>Multivariate</i>: HR: 1.201; 95% CI: 0.691–2.085; $p = 0.5160$</p> <p>Univariate: $p < 0.0001$</p> <p>Univariate: $p = 0.0001$</p> <p>Univariate: $p = 0.0002$</p> <p>Univariate: $p = 0.0014$</p> <p>Univariate: $p = 0.0043$</p> <p>Univariate: $p = 0.0843$</p> <p>Univariate: $p = 0.2566$</p> <p>Univariate: $p = 0.2719$</p> <p>Univariate: $p = 0.3918$</p>
Arrigo, 2011, Retrospective (II)	<ul style="list-style-type: none"> • Single center • 1999 to 2009 • n = 200 • All primaries, including multiple myeloma, lymphoma, plasmacytoma • Average age: 58.9 • 78 F: 122 M 	<ul style="list-style-type: none"> • Univariate: Categorical variables: Kaplan-Meier and Log-rank test; continuous variables: Wald test • Multivariate: Variables with $p < 0.15$ in univariate analyses or predictive significance was previously suggested by other authors were included in Cox PH analysis 	<p>Radiosensitive primary (yes vs. no)</p> <p>Ambulatory status (yes \pm walker, vs. no)</p> <p>Charlson comorbidity index score (0, 1 vs. ≥ 2)</p> <p>Age at time of surgery (years)</p> <p>Cervical spinal location (<i>category not specified</i>)</p> <p>Pathological fracture (present vs. absent)</p> <p>Radiotherapy to surgical site given (yes vs. no)</p> <p>Visceral metastases (present vs. absent)</p> <p>Epidural compression (present vs. absent)</p> <p>Functional health status (independent vs. partially/fully dependent)</p> <p>Frankel grade (E vs. C, D vs. A, B)</p> <p>Primary tumor type (lung vs. breast vs. prostate vs. renal vs. colon vs. other)</p> <p>ASA (ASA 2 vs. ASA 3, 4)</p> <p>Smoker during past year (yes vs. no)</p> <p>Urinary function (retention/incontinence vs. no)</p> <p>Sex (female vs. male)</p> <p>Extraspinal bone metastasis (yes vs. no)</p> <p>Number of vertebrae with metastasis present</p>	<p>Univariate: $p < 0.0001$, <i>Multivariate</i>: HR: 2.557; 95% CI: 1.672–3.912; $p < 0.0001$</p> <p>Univariate: $p < 0.0001$, <i>Multivariate</i>: HR: 2.355; 95% CI: 1.517–3.658; $p = 0.0001$</p> <p>Univariate: $p = 0.0058$, <i>Multivariate</i>: HR: 2.955; 95% CI: 1.341–6.512; $p = 0.0072$</p> <p>Univariate: $p = 0.9936$, <i>Multivariate</i>: HR: 1.001; 95% CI: 0.986–1.016; $p = 0.8956$</p> <p>Univariate: NR, <i>Multivariate</i>: HR: 1.070; 95% CI: 0.693–1.652; $p = 0.7611$</p> <p>Univariate: $p = 0.4813$, <i>Multivariate</i>: HR: 1.408; 95% CI: 0.954–2.078; $p = 0.0853$</p> <p>Univariate: $p = 0.0829$, <i>Multivariate</i>: HR: 0.980; 95% CI: 0.673–1.427; $p = 0.9144$</p> <p>Univariate: $p = 0.3704$, <i>Multivariate</i>: HR: 1.089; 95% CI: 0.754–1.573; $p = 0.6486$</p> <p>Univariate: $p = 0.0916$, <i>Multivariate</i>: HR: 1.201; 95% CI: 0.691–2.085; $p = 0.5160$</p> <p>Univariate: $p < 0.0001$</p> <p>Univariate: $p = 0.0001$</p> <p>Univariate: $p = 0.0002$</p> <p>Univariate: $p = 0.0014$</p> <p>Univariate: $p = 0.0043$</p> <p>Univariate: $p = 0.0843$</p> <p>Univariate: $p = 0.2566$</p> <p>Univariate: $p = 0.2719$</p> <p>Univariate: $p = 0.3918$</p>

(Continued)

Table 2. (Continued)

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method Univariate; Multivariate	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Bollen, 2013, Retrospective (III)	<ul style="list-style-type: none"> • 2 centers • January 2001 to December 2010 • n = 106 • All primaries (inclusion of hematologic primaries is not specified) • Mean age: 59.0 • 53 F; 53 M 	<ul style="list-style-type: none"> • Univariate: Kaplan-Meier and Log-rank test • Multivariate: Cox PH model, backward stepwise procedure was performed using modified primary tumor Tomita grade, visceral metastasis, and KPS 	<p>Modified primary tumor Tomita grade (slow vs. moderate vs. rapid)</p> <p>KPS (80–100% vs. 50–70% vs. 10–40%)</p> <p>Visceral metastases (absent vs. present)</p> <p>Primary tumor: Tokuhashi revised</p> <p>Primary tumor: van der Linden modified</p> <p>Primary tumor: Bauer modified</p> <p>Tomita visceral metastases</p> <p>Age (<65 vs. ≥ 65 years)</p> <p>Tomita bone metastases (solitary spinal ± extra-spinal vs. multiple spinal ± extra-spinal metastasis)</p> <p>Extra-spinal bone metastases (0 vs. 1–2 vs. ≥3)</p> <p>Number of spinal metastases (1 vs. 2 vs. ≥ 3)</p> <p>Frankel classification (A, B vs. C, D vs. E)</p> <p>Spinal location (C-T6 vs. T7-L)</p> <p>Sex (male vs. female)</p>	<p>Univariate: p < 0.0001, Multivariate: rapid vs. slow; HR: 3.1; 95% CI: 1.6–6.2; p = 0.001, mod. vs. slow; HR: 1.7; 95% CI: 0.9–3.3; p = 0.099</p> <p>Univariate: p = 0.169, Multivariate: KPS 10–40 vs. 80–100%; HR: 2.7; 95% CI: 1.1–6.6; p = 0.025, KPS 50–70 vs. 80–100%; HR: 1.3; 95% CI: 0.8–2.1; p = 0.292</p> <p>Univariate: p = 0.014, Multivariate: HR: 1.7; 95% CI: 1.0–2.9; p = 0.033</p> <p>Univariate: p = 0.0001</p> <p>Univariate: p = 0.0002</p> <p>Univariate: p = 0.0008</p> <p>Univariate: p = 0.027</p> <p>Univariate: p = 0.089</p> <p>Univariate: p = 0.946</p> <p>Univariate: p = 0.970</p> <p>Univariate: p = 0.860</p> <p>Univariate: p = 0.196</p> <p>Univariate: p = 0.163</p> <p>Univariate: p = 0.159</p> <p>Univariate: HR: 0.98; 95% CI: 0.96–1.00; p-value: NR, Multivariate: HR: 0.97; 95% CI: 0.95–0.99; p-value: NR</p> <p>Univariate: HR: 1.41; 95% CI: 1.10–1.79; p-value: NR, Multivariate: HR: 1.53; 95% CI: 1.20–1.97; p-value: NR</p> <p>Univariate: HR: 1.51; 95% CI: 1.17–1.95; p-value: NR, Multivariate: HR: 1.49; 95% CI: 1.14–1.95; p-value: NR</p> <p>Univariate: HR: 0.48; 95% CI: 0.32–0.72; p-value: NR, Multivariate: HR: 0.54; 95% CI: 0.34–0.87; p-value: NR</p> <p>Univariate: HR: 0.47; 95% CI: 0.28–0.79; p-value: NR, Multivariate: reported not significant, no results provided</p> <p>Univariate: HR: 0.61; 95% CI: 0.37–1.00; p-value: NR, Multivariate: reported not significant, no results provided</p> <p>Univariate: HR: 0.71; 95% CI: 0.50–1.00; p-value: NR, Multivariate: reported not significant, no results provided</p> <p>Univariate: HR: 0.99; 95% CI: 0.98–1.01; p-value: NR</p> <p>Univariate: HR: 0.73; 95% CI: 0.50–1.07; p-value: NR</p> <p>Univariate: HR: 1.14; 95% CI: 0.74–1.78; p-value: NR</p> <p>Univariate: HR: 0.92; 95% CI: 0.75–1.14; p-value: NR</p> <p>Univariate: HR: 1.05; 95% CI: 0.97–1.14; p-value: NR</p> <p>Univariate: HR: 0.99; 95% CI: 0.73–1.34; p-value: NR</p>
Cahill, 2011, Retrospective (III)	<ul style="list-style-type: none"> • 2 centers • 1986 to 2005 • n = 379 • Breast cancer • Mean age: 72 • 379 F; 0 M 	<ul style="list-style-type: none"> • Cox PH model for uni- and multivariate analyses • Variables with p < 0.10 in univariate analyses were included in multivariate analysis 	<p>Time interval from cancer diagnosis to surgery (year)</p> <p>Admission to hospital (emergency room vs. no)</p> <p>Histologic grade (poor/undifferentiated vs. well/moderately differentiated)</p> <p>Progesterone receptors (positive vs. negative)</p> <p>Estrogen receptors (positive vs. negative)</p> <p>Estrogen receptors (unknown vs. negative)</p> <p>Progesterone receptors (unknown vs. negative)</p> <p>Age (year)</p> <p>Race (white vs. non-white)</p> <p>Living area (rural vs. no)</p> <p>Marital status (married vs. no)</p> <p>Charlton comorbidity score (per unit increase)</p> <p>Stage 4 disease at breast cancer diagnosis</p>	<p>Univariate: HR: 1.41; 95% CI: 1.10–1.79; p-value: NR, Multivariate: HR: 1.53; 95% CI: 1.20–1.97; p-value: NR</p> <p>Univariate: HR: 1.51; 95% CI: 1.17–1.95; p-value: NR, Multivariate: HR: 1.49; 95% CI: 1.14–1.95; p-value: NR</p> <p>Univariate: HR: 0.48; 95% CI: 0.32–0.72; p-value: NR, Multivariate: HR: 0.54; 95% CI: 0.34–0.87; p-value: NR</p> <p>Univariate: HR: 0.47; 95% CI: 0.28–0.79; p-value: NR, Multivariate: reported not significant, no results provided</p> <p>Univariate: HR: 0.61; 95% CI: 0.37–1.00; p-value: NR, Multivariate: reported not significant, no results provided</p> <p>Univariate: HR: 0.71; 95% CI: 0.50–1.00; p-value: NR, Multivariate: reported not significant, no results provided</p> <p>Univariate: HR: 0.99; 95% CI: 0.98–1.01; p-value: NR</p> <p>Univariate: HR: 0.73; 95% CI: 0.50–1.07; p-value: NR</p> <p>Univariate: HR: 1.14; 95% CI: 0.74–1.78; p-value: NR</p> <p>Univariate: HR: 0.92; 95% CI: 0.75–1.14; p-value: NR</p> <p>Univariate: HR: 1.05; 95% CI: 0.97–1.14; p-value: NR</p> <p>Univariate: HR: 0.99; 95% CI: 0.73–1.34; p-value: NR</p>

(Continued)

Table 2. (Continued)

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method Multivariate; Multivariate:	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Chen, 2010, Retrospective (III)	<ul style="list-style-type: none"> • Single center • January 2001 to December 2007 • n = 41 • Hepatocellular carcinoma • Mean age: 53.15 • 9 F: 32 M 	<ul style="list-style-type: none"> • Univariate: Kaplan-Meier and Log-rank test • Multivariate: Variables with p < 0.05 in univariate analyses were included in the multivariate Cox PH analysis 	<p>Serum albumin (< 37 vs. ≥ 37 g/L)</p> <p>Lactate dehydrogenase (< 200 vs. ≥ 200 U/L)</p> <p>Number of spinal metastases (1 vs. ≥ 2)</p> <p>KPS (< 70% vs. > 70%)</p> <p>Sex (female vs. male)</p> <p>Age (year)</p> <p>Metastasis to vital organs (present vs. absent)</p> <p>Extra-spinal bone metastases (0 vs. 1–2 vs. ≥ 3)</p> <p>Frankel score (A, B, vs. C, D vs. E)</p> <p>Pathologic fracture (present vs. absent)</p> <p>Aspartate aminotransferase (< 40 vs. ≥ 40 U/L)</p> <p>Alanine transaminase (< 40 vs. ≥ 40 U/L)</p> <p>Spinal levels of metastasis (cervical vs. thoracic vs. lumbar vs. sacral)</p>	<p>Univariate: p = 0.003. Multivariate: HR: 0.295; 95% CI: 0.106–0.819; p = 0.019</p> <p>Univariate: p = 0.044. Multivariate: HR: 5.626; 95% CI: 1.562–20.265; p = 0.008</p> <p>Univariate: p = 0.020. Multivariate: HR: 1.679; 95% CI: 0.647–4.354; p = 0.287</p> <p>Univariate: p = 0.004. Multivariate: HR: 0.819; 95% CI: 0.374–1.791; p = 0.616</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p> <p>Univariate: NR</p>
Ornalc, 2012, Retrospective (III)	<ul style="list-style-type: none"> • Single center • September 2003 to September 2010 • n = 53 • Hormone refractory prostate cancer • Mean age: 68 • 0 F: 53 M 	<ul style="list-style-type: none"> • Univariate: Kaplan-Meier and using Log-rank test; Cox PH model • Multivariate: All variables from univariate analyses were included in the multivariate Cox PH analysis 	<p>KPS (80–100% vs. 50–70%)</p> <p>Visceral metastasis (absent vs. present)</p> <p>Serum PSA (< 200 vs. ≥ 200 ng/ml)</p> <p>Age (< 71 vs. ≥ 71)</p> <p>Time interval from primary tumor diagnosis to surgery (< 36 vs. ≥ 36 mo)</p> <p>Ambulatory status (ambulatory vs. non-ambulatory)</p>	<p>Univariate: Log-rank test: p = 0.0003; Cox: HR: 4.66; 95% CI: 1.90–11.44; p = 0.001. Multivariate: HR: 3.97; 95% CI: 1.57–10.04; p = 0.004</p> <p>Univariate: Log-rank test: p = 0.0002; Cox: HR: 2.52; 95% CI: 1.35–4.70; p = 0.004. Multivariate: HR: 1.80; 95% CI: 0.93–3.46; p = 0.08</p> <p>Univariate: Log-rank test: p = 0.015; Cox: HR: 2.08; 95% CI: 1.13–3.82; p = 0.019. Multivariate: HR: 1.47; 95% CI: 0.79–2.75; p = 0.22</p> <p>Univariate: Log-rank test: p = 0.85; Cox: HR: 0.95; 95% CI: 0.55–1.65; p = 0.85. Multivariate: HR: 0.89; 95% CI: 0.49–1.64; p = 0.72</p> <p>Univariate: Log-rank test: p = 0.87; Cox: HR: 0.96; 95% CI: 0.55–1.67; p = 0.088. Multivariate: HR: 1.29; 95% CI: 0.70–2.39; p = 0.41</p> <p>Univariate: Log-rank test: p = 0.31; Cox: HR: 1.50; 95% CI: 0.67–3.37; p = 0.32. Multivariate: HR: 0.90; 95% CI: 0.38–2.17; p = 0.82</p> <p>Univariate: NR. Multivariate: HR: 1.01; 95% CI: 1.01 to 1.02; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 1.48; 95% CI: 1.24 to 1.77; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 3.17; 95% CI: 2.57 to 3.90; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 2.71; 95% CI: 1.79 to 4.13; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 2.06; 95% CI: 1.58 to 2.68; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 3.50; 95% CI: 2.07 to 5.93; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 2.06; 95% CI: 1.44–2.97; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 1.38; 95% CI: 1.08–1.76; p = 0.0092</p> <p>Univariate: NR. Multivariate: HR: 2.26; 95% CI: 1.73–2.95; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 1.19; 95% CI: 1.01–1.41; p = 0.0377</p> <p>Univariate: p < 0.0001. Multivariate: HR: 2.36; 95% CI: 1.67–3.35; p < 0.001</p>
Finkstein, 2003, Retrospective (III)	<ul style="list-style-type: none"> • Single center • July 1991 and March 1998 • n = 987 • All primaries including lymphoma and myeloma • Mean age: 60.3 • F: M—NR 	<ul style="list-style-type: none"> • Univariate: Bivariate analysis to assess unadjusted relationship between potential predictor and survival • Multivariate: Cox PH model 	<p>Age (year)</p> <p>Gender (female vs. male)</p> <p>Lung (lung vs. other)</p> <p>Melanoma (melanoma vs. other)</p> <p>Breast (breast vs. other)</p> <p>Stomach (stomach vs. other)</p> <p>Colon (colon vs. other)</p> <p>Prostate (prostate vs. other)</p> <p>Kidney (kidney vs. other)</p> <p>Neurologic deficit (no vs. yes)</p> <p>Primary tumor (favorable, i.e. > 20 mo MS, included: myeloma, thyroid cancer, renal cell cancer, breast cancer, and prostate, vs. poor prognosis, i.e. < 20 mo MS, included other primaries)</p> <p>Pain (without pain vs. pain)</p> <p>Paresis (nonparetic vs. paretic)</p> <p>Walking status (walking without vs. walking with support or non-walking)</p>	<p>Univariate: NR. Multivariate: HR: 1.01; 95% CI: 1.01 to 1.02; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 1.48; 95% CI: 1.24 to 1.77; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 3.17; 95% CI: 2.57 to 3.90; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 2.71; 95% CI: 1.79 to 4.13; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 2.06; 95% CI: 1.58 to 2.68; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 3.50; 95% CI: 2.07 to 5.93; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 2.06; 95% CI: 1.44–2.97; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 1.38; 95% CI: 1.08–1.76; p = 0.0092</p> <p>Univariate: NR. Multivariate: HR: 2.26; 95% CI: 1.73–2.95; p = 0.0001</p> <p>Univariate: NR. Multivariate: HR: 1.19; 95% CI: 1.01–1.41; p = 0.0377</p> <p>Univariate: p < 0.0001. Multivariate: HR: 2.36; 95% CI: 1.67–3.35; p < 0.001</p> <p>Univariate: p = 0.0283. Multivariate: HR: 2.53; 95% CI: 1.12 to 7.26; p = 0.0228</p> <p>Univariate: p = 0.0003. Multivariate: HR: 1.79; 95% CI: 1.11 to 2.96; p = 0.0164</p> <p>Univariate: p = 0.0283. Multivariate: HR: 0.97; 95% CI: 0.59 to 1.60; p = 0.889</p>

(Continued)

Table 2. (Continued)

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method Multivariate	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Leithner, 2008, Prospective (III)	<ul style="list-style-type: none"> • 3 centers • January 1998 to September 2006 • 2 analyses: (i) including myeloma (n = 69) and (ii) excluding myeloma (n = 59) • All other primaries, including non-Hodgkin lymphoma • Mean age: 60 • 32 F: 37 M 	<ul style="list-style-type: none"> • Univariate: Kaplan-Meier and Log-rank test • Multivariate: Cox PH model 	<p>Primary tumor Tomita grade (rapid vs. moderate vs. slow)</p> <p>Visceral metastases present vs. absent)</p> <p>Pathological fracture (present vs. absent)</p> <p>Number of spinal metastases (> 1 vs. 1)</p> <p>Number of extraspinal bone metastases (≥ 1 vs. none)</p> <p>Karnofsky score (low vs. intermediate vs. high)</p> <p>Neurologic symptoms (MRC 0-3/5 vs. 4-5/5)</p> <p>Spinal localisation (cervical vs. thoracic vs. lumbar)</p> <p>Frankel grade (A, B vs. C, D vs. E)</p>	<p>Including myeloma: <i>Univariate</i>: p < 0.001. <i>Multivariate</i>: overall: p < 0.001, mod. vs. slow: HR: 1.07; 95% CI: 0.51–2.22; p = 0.857, rapid vs. slow: HR: 9.32; 95% CI: 3.87–22.5; p < 0.001. Excluding myeloma: <i>Univariate</i>: p < 0.001. <i>Multivariate</i>: overall: p < 0.001, mod. vs. slow: HR: 0.56; 95% CI: 0.26–1.21; p = 0.14, rapid vs. slow: HR: 9.32; 95% CI: 3.87–22.5; p < 0.001</p> <p>Including myeloma: <i>Univariate</i>: p = 0.002. <i>Multivariate</i>: HR: 2.17; 95% CI: 1.15–4.09; p = 0.017. Excluding myeloma: <i>Univariate</i>: p = 0.004. <i>Multivariate</i>: HR: 2.42; 95% CI: 1.25–4.64; p = 0.008</p> <p>Including myeloma: <i>Univariate</i>: p = 0.929. <i>Multivariate</i>: HR: 1.3; 95% CI: 0.68–2.49; p = 0.426. Excluding myeloma: <i>Univariate</i>: p = 0.131. <i>Multivariate</i>: HR: 1.58; 95% CI: 0.8–3.09; p = 0.182</p> <p>Including myeloma: <i>Univariate</i>: p = 0.311. <i>Multivariate</i>: HR: 1.37; 95% CI: 0.52–3.63; p = 0.521. Excluding myeloma: <i>Univariate</i>: p = 0.923. <i>Multivariate</i>: HR: 0.49; 95% CI: 0.17–1.4; p = 0.185</p> <p>Including myeloma: <i>Univariate</i>: p = 0.774. <i>Multivariate</i>: HR: 0.95; 95% CI: 0.32–2.73; p = 0.916. Excluding myeloma: <i>Univariate</i>: p = 0.457. <i>Multivariate</i>: HR: 3.16; 95% CI: 0.96–10.4; p = 0.058</p> <p>Including myeloma: <i>Univariate</i>: p = 0.027. <i>Multivariate</i>: overall: p = 0.08, intermediate vs. high: HR: 1.8; 95% CI: 0.49–6.55; p = 0.375, low vs. high: HR: 3.24; 95% CI: 0.89–11.8; p = 0.075. Excluding myeloma: <i>Univariate</i>: p < 0.001. <i>Multivariate</i>: overall: p = 0.096, intermediate vs. high: HR: 1.35; 95% CI: 0.35–5.15; p = 0.665, low vs. high: HR: 2.54; 95% CI: 0.68–9.43; p = 0.163</p> <p>Including myeloma: <i>Univariate</i>: p = 0.922. <i>Multivariate</i>: HR: 1.33; 95% CI: 0.69–2.54; p = 0.386. Excluding myeloma: <i>Univariate</i>: p = 0.982. <i>Multivariate</i>: HR: 1.02; 95% CI: 0.51–2.02; p = 0.952</p> <p>Including myeloma: <i>Univariate</i>: p = 0.638. Excluding myeloma: <i>Univariate</i>: p = 0.371</p> <p>Including myeloma: <i>Univariate</i>: p = 0.930. Excluding myeloma: <i>Univariate</i>: p = 0.976</p> <p><i>Univariate</i>: p = 0.000. <i>Multivariate</i>: HR: 0.273; 95% CI: 0.164–0.454; p = 0.000</p> <p><i>Univariate</i>: p = 0.001. <i>Multivariate</i>: HR: 2.039; 95% CI: 1.361–3.055; p = 0.001</p> <p><i>Univariate</i>: p = 0.000. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.018. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.000. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.008. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.018. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.038. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.468</p> <p><i>Univariate</i>: p = 0.686</p> <p><i>Univariate</i>: p = 0.827</p> <p><i>Univariate</i>: p = 0.062</p> <p><i>Univariate</i>: p = 0.056</p> <p><i>Univariate</i>: p = 0.283</p>
Liang, 2013, Retrospective (III)	<ul style="list-style-type: none"> • Single center • February 2000 to September 2010 • n = 92 patients ≥ 60 years old • All primaries, including one lymphoma • Mean age: 68 • 39 F: 53 M 	<ul style="list-style-type: none"> • Univariate: Kaplan-Meier and Log-rank test • Multivariate: Variables with p < 0.05 in univariate analyses were included in the multivariate Cox PH analysis 	<p>Original Tokuhashi score (1–4 points vs. 5–8 points vs. 9–12 points)</p> <p>Primary tumor Tomita grade (rapid vs. moderate vs. slow)</p> <p>Revised Tokuhashi score (1–8 vs. 9–11 vs. 12–15 points)</p> <p>Tomita stage (intravertebral vs. perivertebral vs. adjacent vertebral vs. multiple vertebral involvement)</p> <p>Tomita score (2–3 vs. 4–5 vs. 6–7 vs. 8–10 points)</p> <p>Frankel score (A, B vs. C vs. D, E)</p> <p>VAS score (1–4 vs. 5–7 vs. 8–10 points)</p> <p>Extraspinal bone involved</p> <p>Age (≥ 60 to < 70 vs. ≥ 70 years)</p> <p>KPS (0–40% vs. 50–70% vs. 80–100%)</p> <p>Visceral metastasis</p> <p>Primary surgery</p> <p>Pathological fracture</p> <p>Surgical complications</p>	<p><i>Univariate</i>: p = 0.000. <i>Multivariate</i>: HR: 0.273; 95% CI: 0.164–0.454; p = 0.000</p> <p><i>Univariate</i>: p = 0.001. <i>Multivariate</i>: HR: 2.039; 95% CI: 1.361–3.055; p = 0.001</p> <p><i>Univariate</i>: p = 0.000. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.018. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.000. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.008. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.018. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.038. <i>Multivariate</i>: non-significant at p < 0.05 but result NR</p> <p><i>Univariate</i>: p = 0.468</p> <p><i>Univariate</i>: p = 0.686</p> <p><i>Univariate</i>: p = 0.827</p> <p><i>Univariate</i>: p = 0.062</p> <p><i>Univariate</i>: p = 0.056</p> <p><i>Univariate</i>: p = 0.283</p>

(Continued)

Table 2. (Continued)

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Mollahosseini, 2011, Prospective (III)	<ul style="list-style-type: none"> Single center February 2007 to March 2009 n = 109 All primaries, (primaries included in "others" are not specified, thus inclusion of hematologic primaries is unclear) Mean age: 57 58 F; 53 M 	<ul style="list-style-type: none"> Univariate: NR Multivariate: Cox, PH model 2 Cox PH models were created, which included: (1) Age, sex and Tokuhashi score; (2) the 6 variables of the Tokuhashi revised score 	<p>(1) Age (continuous), Sex (female vs. male), Tokuhashi score (continuous)</p> <p>(2) Cox PH model including the 6 variables comprised in the Tokuhashi revised score: -2 log-likelihood = 376.051, $\chi^2 = 57.48$, df = 1; p < .001. Age and sex: reported to be non-significant at p < 0.05 but result NR</p> <p>Multivariate: only Tokuhashi revised score: -2 log-likelihood = 376.051, $\chi^2 = 57.48$, df = 1; p < .001. Age and sex: reported to be non-significant at p < 0.05 but result NR</p> <p>Multivariate: HR: 0.54; 95% CI: 0.32–0.92; p = 0.022</p> <p>Multivariate: HR: 0.4; 95% CI: 0.25–0.65; p < 0.001</p> <p>Multivariate: HR: 0.64; 95% CI: 0.48–0.85; p = 0.002</p> <p>Multivariate: HR: 0.62; 95% CI: 0.54–0.72; p < 0.001</p>	
Nemelic, 2014, Retrospective (III)	<ul style="list-style-type: none"> Single center 2000 to 2010 n = 81 All primaries including myeloma Median age: 59 37 F; 44 M 	<ul style="list-style-type: none"> Cox PH model for both uni- and multivariate Variables with p < 0.20 in univariate analyses were included in the multivariate analysis 	<p>Site of primary cancer (breast, renal, myeloma, lung, prostate, colorectal, other)</p> <p>ASIA score (B vs. C vs. D vs. E)</p> <p>Visceral metastases (present vs. absent)</p> <p>Multiple metastases</p> <p>Cervical location (yes vs. no)</p> <p>Thoracic location (yes vs. no)</p> <p>Lumbar location (yes vs. no)</p> <p>Sacral location (yes vs. no)</p> <p>Radiotherapy (received vs. no)</p> <p>Surgical indication (pain vs. instability vs. neurologic impairment vs. neurologic impairment with pain vs. pain with instability vs. neurologic impairment with instability)</p> <p>Primary tumor Tomita grade (slow vs. moderate vs. rapid)</p> <p>Visceral metastasis to vital organs (no vs. treatable by operation or trans-arterial embolisation vs. untreatable)</p> <p>Bone metastases, spinal metastasis included (solitary/ isolated spinal with any other bone metastasis vs. multiple spinal metastasis ± other bone metastasis)</p>	<p>Multivariate: p = 0.686 (HR and 95% CI are NR)</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.01. Multivariate: overall: p < 0.05. renal vs. breast: HR: 2.02; 95% CI: 0.95–4.30; p-value: NR. myeloma vs. breast: HR: 0.22; 95% CI: 0.05–0.95; p-value: NR. lung vs. breast: HR: 4.52; 95% CI: 1.73–11.78; p-value: NR. prostate vs. breast: HR: 1.54; 95% CI: 0.61–3.86; p-value: NR. colorectal vs. breast: HR: 5.53; 95% CI: 2.23–13.74; p-value: NR. others vs. breast: HR: 2.53; 95% CI: 1.6–5.53; p-value: NR</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.01. Multivariate: overall: p < 0.05. ASIA D vs. E: HR: 1.75; 95% CI: 0.63–4.81; p-value: NR. ASIA C vs. E: HR: 13.03; 95% CI: 0.97–3.20; p-value: NR, but in the text: ASIA C vs. E: 95% CI: 4.57–37.16. ASIA B vs. E: HR: 1.75; 95% CI: 0.63–4.81; p-value: NR</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.18. Multivariate: HR: NR; 95% CI: NR; p = 0.57</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.82</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.89</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.79</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.65</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.95</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.33</p> <p>Univariate: HR: NR; 95% CI: NR; p = 0.56</p> <p>Multivariate: overall: p < 0.05. moderate vs. slow: HR: 1.82; 95% CI: NR; p-value: NR. rapid vs. slow: HR: 4.08; 95% CI: NR; p-value: NR</p> <p>Multivariate: overall: p < 0.05. treatable vs. no: HR: 1.00; 95% CI: NR; p-value: NR. untreatable vs. no: HR: 1.90; 95% CI: NR; p-value: NR</p> <p>Multivariate: HR: 1.94; 95% CI: NR; p < 0.05</p>
Tomita, 2001, Retrospective (II)	<ul style="list-style-type: none"> Single center 1987–end of 1992 n = 57 All primaries, no hematologic cancer included Mean age: 56.3 36 F; 31 M 	<ul style="list-style-type: none"> Multivariate: Cox, PH analysis 	<p>Primary tumor Tomita grade (slow vs. moderate vs. rapid)</p> <p>Visceral metastasis to vital organs (no vs. treatable by operation or trans-arterial embolisation vs. untreatable)</p> <p>Bone metastases, spinal metastasis included (solitary/ isolated spinal with any other bone metastasis vs. multiple spinal metastasis ± other bone metastasis)</p>	<p>Multivariate: overall: p < 0.05. moderate vs. slow: HR: 1.82; 95% CI: NR; p-value: NR. rapid vs. slow: HR: 4.08; 95% CI: NR; p-value: NR</p> <p>Multivariate: overall: p < 0.05. treatable vs. no: HR: 1.00; 95% CI: NR; p-value: NR. untreatable vs. no: HR: 1.90; 95% CI: NR; p-value: NR</p> <p>Multivariate: HR: 1.94; 95% CI: NR; p < 0.05</p>

(Continued)

Table 2. (Continued)

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method Univariate; Multivariate	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Williams, 2009, Retrospective (III)	<ul style="list-style-type: none"> Single center 1993–2005 n = 44 Prostate cancer Median age: 68 0 F: 44 M 	<ul style="list-style-type: none"> Cox PH model for both uni- and multivariate Variables with p < 0.15 in univariate analyses were included in multivariate analysis and tested through a backward stepwise selection 	<p>Gleason score (< 8, median score = 8)</p> <p>Total number metastases (≤ 5, median = 5)</p> <p>Lymph node metastases at time of spinal surgery (absence vs. presence)</p> <p>Degree compression of spinal canal (≤ 25%)</p>	<p>Univariate: NR. Multivariate: HR: NR; 95% CI: NR; p = 0.002</p> <p>Univariate: NR. Multivariate: HR: NR; 95% CI: NR; p = 0.001</p> <p>Univariate: NR. Multivariate: HR: NR; 95% CI: NR; p = 0.04</p> <p>Univariate: NR. Multivariate: HR: NR; 95% CI: NR; p = 0.001</p>
Chen, 2015, Retrospective (III)	<ul style="list-style-type: none"> Single center November 2000 to March 2010 n = 50 NSCLC Mean age: 61.6 16 F: 34 M 	<ul style="list-style-type: none"> Cox PH model for both uni- and multivariate Variables with p < 0.05 in univariate analyses were included in multivariate analysis Although palsy score was not significant on univariate analysis, it was considered to be an important factor, so it was included in multivariate analysis 	<p>KPS (10–40% vs. 50–70% vs. 80–100%)</p> <p>Age (≤ 54 vs. 55–74 vs. ≥ 75)</p> <p>Frankel score (A, B vs. C, D)</p> <p>Tumor histology (adenocarcinoma vs. non-adenocarcinoma)</p> <p>Sex (female vs. male)</p> <p>Number of vertebra involved (< 3 vs. ≥ 3)</p> <p>Other bone metastasis (absent vs. present)</p> <p>Visceral metastasis (absent vs. present)</p> <p>BMI (underweight vs. eutrophic vs. overweight/obese)</p>	<p>Univariate: 50–70 vs. 10–40%; HR: 0.43; 95% CI: 0.18–1.03; p = 0.059, 80–100 vs. 10–40%; HR: 0.09; 95% CI: 0.03–0.26; p < 0.001. Multivariate: 50–70 vs. 10–40%; HR: 0.52; 95% CI: 0.16–1.74; p = 0.289, 80–100 vs. 10–40%; HR: 0.14; 95% CI: 0.03–0.54; p = 0.004</p> <p>Univariate: 55–74 vs. ≤ 54; HR: 1.16; 95% CI: 0.60–2.25; p = 0.659, ≥ 75 vs. ≤ 54; HR: 3.28; 95% CI: 1.37–7.82; p = 0.008. Multivariate: 55–74 vs. ≤ 54; HR: 0.78; 95% CI: 0.37–1.64; p = 0.512, ≥ 75 vs. ≤ 54; HR: 1.22; 95% CI: 0.37–4.05; p = 0.748</p> <p>Univariate: HR: 1.18; 95% CI: 0.49–2.83; p = 0.706. Multivariate: HR: 1.23; 95% CI: 0.50–3.03; p = 0.653</p> <p>Univariate: HR: 0.38; 95% CI: 0.20–0.71; p = 0.003. Multivariate: HR: 0.59; 95% CI: 0.28–1.25; p = 0.167</p> <p>Univariate: HR: 0.61; 95% CI: 0.33–1.14; p = 0.120</p> <p>Univariate: HR: 0.70; 95% CI: 0.39–1.25; p = 0.228</p> <p>Univariate: HR: 0.83; 95% CI: 0.46–1.49; p = 0.531</p> <p>Univariate: HR: 1.08; 95% CI: 0.52–2.23; p = 0.837</p> <p>Univariate: eutrophic vs. underweight; HR: 1.03; 95% CI: 0.39–2.68; p = 0.958, overweight vs. underweight; HR: 0.72; 95% CI: 0.25–2.05; p = 0.538</p> <p>Univariate: Log-rang test: p < 0.001. Cox PH model: HR: 2.78; 95% CI: 1.54–5.02; p < 0.001. Multivariate: HR: 2.18; 95% CI: 1.15–4.16; p = 0.017</p> <p>Univariate: Log-rang test: p < 0.001. Cox PH model: HR: 2.46; 95% CI: 1.39–4.35; p = 0.002. Multivariate: HR: 2.05; 95% CI: 1.11–3.76; p = 0.021</p> <p>Univariate: Log-rang test: p = 0.002. Cox PH model: HR: 2.29; 95% CI: 1.33–3.94; p = 0.003. Multivariate: HR: 2.00; 95% CI: 1.10–3.62; p = 0.022</p> <p>Univariate: Log-rang test: p < 0.001. Cox PH model: HR: 3.44; 95% CI: 1.90–6.22; p = 0.001. Multivariate: HR: 2.70; 95% CI: 1.45–5.03; p = 0.002</p> <p>Univariate: Log-rang test: p = 0.003. Cox PH model: HR: 2.24; 95% CI: 1.30–3.86; p = 0.004. Multivariate: non-significant at p < 0.05 but result NR</p> <p>Univariate: Log-rang test: p = 0.16</p> <p>Univariate: Log-rang test: p = 0.90</p> <p>Univariate: Log-rang test: p = 0.58</p> <p>Univariate: Log-rang test: p = 0.73</p>
Lei, 2015 Retrospective (III) Development of a scoring system	<ul style="list-style-type: none"> Single center May 2005 to May 2015 n = 64 NSCLC Median age: 57 22 F: 42 M 	<ul style="list-style-type: none"> Univariate Kaplan-Meier and Log-rank test; Cox PH model Multivariate Variables with p < 0.05 in univariate analyses were included in the Cox PH model following stepwise selection 	<p>ECOG performance status (1–2 vs. 3–4)</p> <p>Number of vertebrae involved (1–2 vs. ≥ 3)</p> <p>Visceral metastasis (absent vs. present)</p> <p>Time developing motor deficits before surgery (≤ 14 vs. > 14 days)</p> <p>Ambulatory status (ambulatory vs. non-ambulatory)</p> <p>Age (≤ 57 vs. > 57, median 57 years)</p> <p>Sex (female vs. male)</p> <p>Other bone metastases (absent vs. present)</p> <p>Interval from cancer diagnosis to surgery (≤ 80 vs. > 80 days, median time: 80 days)</p>	<p>Univariate: eutrophic vs. underweight; HR: 1.03; 95% CI: 0.39–2.68; p = 0.958, overweight vs. underweight; HR: 0.72; 95% CI: 0.25–2.05; p = 0.538</p> <p>Univariate: Log-rang test: p < 0.001. Cox PH model: HR: 2.78; 95% CI: 1.54–5.02; p < 0.001. Multivariate: HR: 2.18; 95% CI: 1.15–4.16; p = 0.017</p> <p>Univariate: Log-rang test: p < 0.001. Cox PH model: HR: 2.46; 95% CI: 1.39–4.35; p = 0.002. Multivariate: HR: 2.05; 95% CI: 1.11–3.76; p = 0.021</p> <p>Univariate: Log-rang test: p = 0.002. Cox PH model: HR: 2.29; 95% CI: 1.33–3.94; p = 0.003. Multivariate: HR: 2.00; 95% CI: 1.10–3.62; p = 0.022</p> <p>Univariate: Log-rang test: p < 0.001. Cox PH model: HR: 3.44; 95% CI: 1.90–6.22; p = 0.001. Multivariate: HR: 2.70; 95% CI: 1.45–5.03; p = 0.002</p> <p>Univariate: Log-rang test: p = 0.003. Cox PH model: HR: 2.24; 95% CI: 1.30–3.86; p = 0.004. Multivariate: non-significant at p < 0.05 but result NR</p> <p>Univariate: Log-rang test: p = 0.16</p> <p>Univariate: Log-rang test: p = 0.90</p> <p>Univariate: Log-rang test: p = 0.58</p> <p>Univariate: Log-rang test: p = 0.73</p>

(Continued)

Table 2. (Continued)

1 st Author, Year, Study design (Class of evidence)	Study sample characteristics†	Statistical method Univariate; Multivariate;	Predictive factors assessed‡	Results (HR; 95% CI; p-value)
Lei, 2015, Retrospective (III)	<ul style="list-style-type: none"> • Single center • May 2005 to May 2015 • n = 37 (test group) • Lung cancer, including NSCLC (n = 33) and SCLC (n = 4) • Median age: 57 • 12 F: 25 M 	<ul style="list-style-type: none"> • Univariate: Kaplan-Meier and Log-rank test • Multivariate: Variables with p < 0.05 in univariate analyses were included in the multivariate Cox PH model following a stepwise selection 	<p>Visceral metastasis (absent vs. present)</p> <p>Time developing motor deficits before surgery (≤ 14 vs. >14 days)</p> <p>Ambulatory status (ambulatory vs. non-ambulatory)</p> <p>Number of vertebrae involved (1–2 vs. ≥ 3)</p> <p>ECOG performance status (1–2 vs. 3–4)</p> <p>Age (≤ 57 vs. >57, median 57 years)</p> <p>Sex (female vs. male)</p> <p>Histology (adenocarcinoma vs. non-adenocarcinoma)</p> <p>Other bone metastases (absent vs. present)</p> <p>Interval from cancer diagnosis to surgery (≤ 80 vs. >80 days, median time: 80 days)</p>	<p>Univariate: p = 0.0118. Multivariate: Risk ratio: 7.913; 95% CI: 2.678–23.382; p = 0.0002</p> <p>Univariate: p < 0.0001. Multivariate: Risk ratio: 4.828; 95% CI: 2.005–11.628; p = 0.0004</p> <p>Univariate: p = 0.0054. Multivariate: Risk ratio: 4.510; 95% CI: 1.757–11.578; p = 0.0017</p> <p>Univariate: p = 0.0028. Multivariate: non-significant at p < 0.05 but result NR</p> <p>Univariate: p = 0.0002. Multivariate: non-significant at p < 0.05 but result NR</p> <p>Univariate: p = 0.3802</p> <p>Univariate: p = 0.5626</p> <p>Univariate: p = 0.2288</p> <p>Univariate: p = 0.8718</p> <p>Univariate: p = 0.6304</p>

Bolited predictive factors are statistically significant in multivariate analysis at a significance level of p < 0.05

† Study sample characteristics: Number of center(s) involved; Study span; Patients (n); Primary tumor included; Age at surgery; Female:Male (F:M)

‡ For predictive factors used as categorical variables, the referent is underlined only when it was clearly reported in a table or specified in the text.

* The authors report Frankel score as being a statistically significant predictor when they reported setting p < 0.05 as significant.

Abbreviations (alphabetical order): **95% CI**: 95% confidence interval; **ASA**: American society of anesthesiologists physical status classification; **ASIA**: American spinal injury association; **BMI**: body mass index; **ECOG**: Eastern Cooperative Oncology Group; **GTR**: gross-total resection; **HR**: hazard ratio; **KPS**: Karnofsky performance status; **mo**: months; **MRC**: medical research council motor strength scale **MS**: median survival; **NR**: not reported; **NSCLC**: non-small cell lung cancer; **OR**: odd ratio; **PH**: proportional hazard; **PHA**: proportional hazard assumption; **PSA**: prostate-specific antigen; **SCLC**: small cell lung cancer; **SSM**: symptomatic spinal metastasis; **STR**: sub-total resection; **ukn**: unknown; **vs.**: versus

doi:10.1371/journal.pone.0171507.t002

[49], total number of metastases > 5 [49], presence of lymph node metastases[49], and degree of canal compression $> 25\%$ [49]; lung cancer with presence of visceral metastasis, ≤ 14 days from onset of motor deficit to surgery, incapacity to walk independently or with a walking aid [55]; NSCLC with KPS $< 80\%$ [51], ECOG 3–4[41], ≥ 3 vertebral metastases[41], presence of visceral metastasis[41] and ≤ 14 days from onset of motor deficit to surgery[41]; and unknown site of primary tumor with cervical spinal location, Frankel score A, B or C, and presence of extraspinal disease at presentation[47].

Methodological issues

All 17 studies used the Cox proportional hazards (PH) regression method for their multivariate survival analysis. Five studies[24, 43, 46, 47, 49] did not provide a clear definition, measurement or categorization of their predictors, e.g. “High versus Intermediate versus Low KPS” without defining the corresponding KPS numerical range. One study[50] identified CCIS ≥ 2 as a predictor of survival although CCIS ≥ 2 is not a discriminatory factor given that the sole presence of metastatic solid tumor gives a CCIS of 6[58]. Four studies[43, 44, 49, 53] did not clearly report which predictors were assessed using univariate analysis and, among these studies, one[49] did not report any results for these analyses. Three studies[52, 53, 57] did not specify how predictors were selected to enter the multivariate analysis. Four studies[24, 48, 50, 51] did not analyze predictors that were described in the Methods section, and two studies[47, 53] did not clearly distinguish the results from uni- and multivariate analyses. Only three[43, 48, 50] studies mentioned testing for the proportional hazards assumption (PHA). While two[48, 50] of these studies specified the statistical method used to test the PHA, none actually reported their result. One study[43] reported testing for collinearity but reported neither the technique used nor the results. Eight studies [45, 51, 55, 56],[43, 48, 49, 53] did not report how many patients died during follow-up. Among these, four[45, 51, 55, 56] included more predictor degrees of freedom in their multivariate model than their total sample size n divided by 10. In addition, six studies[44, 51, 53–56] included at least one predictor that had ten or less events in a stratum in one of their categorical variable(s). Furthermore, deficiencies in reporting were identified in all 17 studies, including: three studies[47, 49, 53] did not report the hazard ratio or confidence intervals, seven studies[43, 46, 48, 49, 52, 55, 56] studies did not identify the referent stratum for their categorical predictors and 12 studies[24, 41, 44–46, 49, 50, 53–57] did not indicate the directionality of associations (shorter or longer survival).

Overall strength of evidence related to survival

Seven studies examined the preoperative clinical factors associated with survival in patients with SSM from all sites of primary tumor including multiple myeloma (MM). A total of 20 factors were identified, among which 11 were related to the site/histology of the primary tumor [24, 43–45, 50, 56, 57]. Two studies[24, 59] evaluated predictors of survival in patients with SSM from all sites of primary tumors excluding MM and reported three predictors: primary tumor Tomita Grade II and III (original classification), presence of visceral metastases and presence of bone metastases (spinal and extraspinal). The baseline strength of evidence was *Low* for preoperative prognostic factors of survival in studies that considered all sites of primary tumors including or excluding MM. When MM was included, only radioresistant site of primary tumor had a final strength of evidence of *Low*. All other predictors related to the site of primary tumor were downgraded to *Very low* due to high risk of bias related to inconsistency of results. Non-ambulatory status and CCIS ≥ 2 maintained a final strength of evidence of *Low* while the remaining seven predictors were downgraded to *Very low* for at least high

risk of bias. The final strength of evidence for the three predictors of survival for all primaries excluding MM was also *Very low* for at least high risk of bias (Table 3).

Various preoperative factors of survival were identified in multivariate analysis in specific groups of SSM patients. Although two studies examined the preoperative factors of survival in patients with SSM from prostate cancer, they did not consider the same predictors. KPS 50–70%[54], Gleason score > 8[49], total number of metastases > 5[49], presence of lymph node metastases at the time of surgery[49] and degree of canal compression > 25%[49] had a *Low* strength of evidence at baseline and their respective final strength of evidence was *Very low* due to high risk of bias (Table 3). Based on two studies[41, 51], the four predictors of survival for SSM resulting from NSCLC also had a *Low* strength of evidence at baseline. All predictors were downgraded to a *Very low* final strength of evidence: low performance status and ≤ 14 days from onset of motor deficit to surgery because of high risk of bias and ≥ 3 vertebral metastases and presence of visceral metastasis because of high risk of bias and inconsistency (Table 3). Preoperative prognostic factors in patients with (1) unknown site of primary tumor at the time of SSM surgery, (2) breast cancer, (3) HHC, (4) lung cancer, ≥ 60 years old with SSM from heterogenous primary tumors were derived from a single study, all of which had a *Low* strength of evidence at baseline. The final strength of evidence for predictors of survival in breast cancer[48] was *Low* while all the others[46, 47, 52, 55] were downgraded to *Very low* due to high risk of bias[46, 47, 52, 55] and imprecision[47] (Table 4).

Discussion

Summary of findings

To our knowledge, this is the first systematic literature review that has sought to determine the key preoperative predictors of survival (KQ1), neurologic (KQ2), functional (KQ3), and HRQoL (KQ4) outcomes in patients with SSM who underwent surgical treatment. This systematic review identified 17 studies related to our KQ1 that conducted multivariate analysis and reported a total of 46 preoperative prognostic factors of survival in surgical SSM patients. All 17 prognostic studies were rated as having a moderately high risk of bias (Class III evidence). The final strength of the overall body of evidence was graded *low* for 7 and *very low* for the remaining 39 predictors of survival.

In spite of performing a literature search designed to maximize sensitivity, this review was only able to identify studies addressing KQ1. Six studies examined the clinical prognostic factors of functional status (KQ3) and one study isolated predictors of HRQoL (KQ4), but these studies were excluded because they included surgical and/or postoperative predictors. Inclusion of such predictors in the multivariate analysis runs the risk of precluding relevant preoperative predictors from either being selected in the final model or showing statistical significance. Also, final models that retain surgical/postoperative predictors are not relevant in the preoperative period, which is the critical time-point for clinical decision-making. Therefore, while this review had limited success in establishing preoperative prognostic factors of survival, it also highlights the dearth of evidence related to predictors of neurologic, functional, and HRQoL outcomes in surgical SSM patients.

Methodological considerations and recommendations

Due to the nature of cohort studies, prognostic data from these will be biased and may not be generalizable to patients with spinal metastases. Cohort studies are often limited by cost and timescales, and significant losses to follow-up. Spinal centers may cover large geographical areas, and patients may be transferred elsewhere for subsequent oncological treatments. Failure to return for spinal clinic follow-up at prearranged appointment times may be due to travel

Table 3. Overall body of evidence for preoperative predictors of survival in surgical SSM patients from multiple studies.

Negative preoperative predictors	Baseline strength evidence	Univariate consistent	Univariate inconsistent	Multivariate consistent	Multivariate inconsistent	Up-/Downgrade	Final strength evidence
All types of primary tumors, including multiple myeloma[24, 43–45, 50, 56, 57]							
Modified primary tumor Tomita Grade III, i.e. rapid growing tumor*	Low	Bollen, 2013: rapid vs. moderate vs. slow		Bollen, 2013: rapid vs. slow	Bollen, 2013: mod. vs. slow	-1: risk of bias	Very low
Primary tumor Tomita Grade III, i.e. rapid growing tumor**	Low	Leithner, 2008: rapid vs. moderate vs. slow		Leithner, 2008: rapid vs. slow	Leithner, 2008: mod. vs. slow	-1: risk of bias	Very low
Poor prognosis primary tumor***	Low	Hosono, 2005: favorable (myeloma, renal, thyroid, breast, prostate) vs. poor prognosis (other primaries)		Hosono, 2005: favorable (myeloma, renal, thyroid, breast, prostate) vs. poor prognosis (other primaries)		-1: risk of bias	Very low
Radioresistant primary tumor****	Low	Arrigo, 2011: radioresistant vs. radiosensitive		Arrigo, 2011: radioresistant vs. radiosensitive			Low
Lung primary	Low		Arrigo, 2011: lung vs. breast vs. prostate vs. renal vs. colon vs. other	Finkelstein, 2003: lung vs. other		• -1: risk of bias • -1: consistency	Very low
Melanoma primary	Low			Finkelstein, 2003 melanoma vs. other		-1: risk of bias	Very low
Breast primary	Low		Arrigo, 2011: lung vs. breast vs. prostate vs. renal vs. colon vs. other	Finkelstein, 2003 breast vs. other		• -1: risk of bias • -1: consistency	Very low
Stomach primary	Low			Finkelstein, 2003: stomach vs. other		-1: risk of bias	Very low
Colon primary	Low		Arrigo, 2011: lung vs. breast vs. prostate vs. renal vs. colon vs. other	Finkelstein, 2003: colon vs. other		• -1: risk of bias • -1: consistency	Very low
Prostate primary	Low		Arrigo, 2011: lung vs. breast vs. prostate vs. renal vs. colon vs. other	Finkelstein, 2003: prostate vs. other		• -1: risk of bias • -1: consistency	Very low
Kidney primary	Low		Arrigo, 2011: lung vs. breast vs. prostate vs. renal vs. colon vs. other	Finkelstein, 2003: kidney vs. other		• -1: risk of bias • -1: consistency	Very low
Non-ambulatory	Low	Arrigo, 2011: ambulatory ± walking aid vs. not ambulatory		Arrigo, 2011: ambulatory ± walking aid vs. not ambulatory			Low

(Continued)

Table 3. (Continued)

Negative preoperative predictors	Baseline strength evidence	Univariate consistent	Univariate inconsistent	Multivariate consistent	Multivariate inconsistent	Up- / Downgrade	Final strength evidence
Presence of neurologic deficit or palsy or Frankel/ASIA other than E	Low	<ul style="list-style-type: none"> Hosono, 2005: <i>paretic vs. non-paretic</i> Nemec, 2014: <i>ASIA B vs. C vs. D vs. E</i> 	<ul style="list-style-type: none"> Arrigo, 2011: <i>Frankel E vs. C, D vs. A, B</i> Bollen, 2013: <i>Frankel E vs. C, D vs. A, B</i> Leithner, 2008: <i>MRC 0-5/5 vs. 4-5/5</i> Leithner, 2008: <i>Frankel E vs. C, D vs. A, B</i> 	<ul style="list-style-type: none"> Finkelstein, 2003: <i>present vs. absent</i> Hosono, 2005: <i>paretic vs. non-paretic</i> Nemec, 2014: <i>ASIA C vs. E</i> 	<ul style="list-style-type: none"> Leithner, 2008: <i>MRC 0-5/5 vs. 4-5/5</i> Mollahoseini, 2011: <i>Frankel E vs. C, D vs. A, B</i> Nemec, 2014: <i>ASIA D vs. E; ASIA B vs. E</i> 	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Charlson comorbidity index score ≥ 2	Low	Arrigo, 2011: <i>0-1 vs. ≥ 2</i>		Arrigo, 2011: <i>0-1 vs. ≥ 2</i>			Low
KPS 10-40%	Low	Bollen, 2013: <i>rapid vs. moderate vs. slow</i>	<ul style="list-style-type: none"> Arrigo, 2011: <i>independent vs. partially/fully independent functional status</i> Leithner, 2008: <i>low vs. intermediate vs. high</i> 	<ul style="list-style-type: none"> Bollen, 2013: <i>10-40 vs. 80-100%</i> Mollahoseini, 2011: <i>10-40 vs. 50-70 vs. 80-100%</i> 	<ul style="list-style-type: none"> Bollen, 2013: <i>50-70 vs. 80-100%</i> Leithner, 2008: <i>Intermediate vs. high; intermediate vs. low; $p = 0.075$</i> 	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Presence of visceral metastases	Low	<ul style="list-style-type: none"> Bollen, 2013: <i>present vs. absent</i> Leithner, 2008: <i>present vs. absent</i> 	<ul style="list-style-type: none"> Arrigo, 2011: <i>present vs. absent</i> Bollen, 2013: <i>treatable vs. non-treatable vs. absent</i> Nemec, 2014: <i>present vs. absent</i> 	<ul style="list-style-type: none"> Bollen, 2013: <i>present vs. absent</i> Leithner, 2008: <i>present vs. absent</i> Mollahoseini, 2011: <i>treatable vs. non-treatable vs. absent</i> 	<ul style="list-style-type: none"> Arrigo, 2011: <i>present vs. absent</i> Nemec, 2014: <i>present vs. absent</i> 	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Number of spinal metastasis	Low		<ul style="list-style-type: none"> Arrigo, 2011: <i>continuous variable</i> Bollen, 2013: <i>1 vs. 2 vs. ≥ 3</i> Leithner, 2008: <i>1 vs. > 1</i> 	<ul style="list-style-type: none"> Mollahoseini, 2011: <i>1 vs. 2 vs. ≥ 3</i> 	Leithner, 2008: <i>1 vs. > 1</i>	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Older age	Low		<ul style="list-style-type: none"> Arrigo, 2011: <i>continuous variable</i> Bollen, 2013: <i><65 vs. ≥ 65 years</i> 	Finkelstein, 2003: <i>continuous variable</i>	<ul style="list-style-type: none"> Arrigo, 2011: <i>continuous variable</i> Mollahoseini, 2011: <i>continuous variable</i> 	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Male sex	Low		<ul style="list-style-type: none"> Arrigo, 2011: <i>male vs. female</i> Bollen, 2013: <i>male vs. female</i> 	Finkelstein, 2003: <i>male vs. female</i>	<ul style="list-style-type: none"> Mollahoseini, 2011: <i>male vs. female</i> 	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low

(Continued)

Table 3. (Continued)

Negative preoperative predictors	Baseline strength evidence	Univariate consistent	Univariate inconsistent	Multivariate consistent	Multivariate inconsistent	Up- / Downgrade	Final strength evidence
Presence of pain	Low	Hosono, 2005; <i>pain vs. no pain</i>		Hosono, 2005; <i>pain vs. no pain</i>		-1: risk of bias	Very low
All types of primary tumors, excluding multiple myeloma [24,53]							
Primary tumor Grade II and III, i.e. moderate and rapid growing tumor, respectively	Low	Leithner, 2008		<ul style="list-style-type: none"> Tomita, 2001: <i>mod. vs. slow; rapid vs. slow</i> Leithner, 2008: <i>rapid vs. slow</i> 	Leithner, 2008: <i>mod. vs. slow</i>	-1: risk of bias	Very low
Presence of visceral metastases	Low	Leithner, 2008: <i>present vs. absent</i>		<ul style="list-style-type: none"> Tomita, 2001: <i>treatable vs. non-treatable vs. absent</i> Leithner, 2008: <i>present vs. absent</i> 		-1: risk of bias	Very low
Presence of bone metastases, both spinal and extraspinal	Low		Leithner, 2008: (a) number of spinal metastases (> 1 vs. 1); (b) number of extraspinal bone metastases (≥ 1 vs. 1)	Tomita, 2001: <i>solitary spinal \pm extra-spinal vs. multiple spinal \pm extra-spinal metastasis</i>	Leithner, 2008: (a) number of spinal metastases (> 1 vs. 1); (b) number of extraspinal bone metastases (≥ 1 vs. 1); p = 0.058	<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Prostate cancer [49,54]							
50–70% KPS	Low					-1: risk of bias	Very low
Gleason score > 8	Low					-1: risk of bias	Very low
Total number metastases > 5	Low					-1: risk of bias	Very low
Presence of metastases to lymph node at the time of spinal surgery	Low					-1: risk of bias	Very low
> 25% spinal canal compression	Low					-1: risk of bias	Very low
NSCLC [41, 51]							
Low performance status	Low	<ul style="list-style-type: none"> Chen, 2015: KPS: 80–100 vs. 10–40% Lei, 2015: ECOG: 1–2 vs. 3–4 	Chen, 2015: KPS: 50–70 vs. 10–40%; p = 0.059	<ul style="list-style-type: none"> Chen, 2015: KPS: 80–100 vs. 10–40% Lei, 2015: ECOG: 1–2 vs. 3–4 	Chen, 2015: KPS: 50–70 vs. 10–40%	-1: risk of bias	Very low
≥ 3 vertebrae involved	Low	Lei, 2015: 1–2 vs. ≥ 3	Chen, 2015	Lei, 2015: 1–2 vs. ≥ 3		<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low
Presence of visceral metastasis	Low	Lei, 2015	Chen, 2015	Lei, 2015		<ul style="list-style-type: none"> -1: risk of bias -1: consistency 	Very low

(Continued)

Table 3. (Continued)

Negative preoperative predictors	Baseline strength evidence	Univariate consistent	Univariate inconsistent	Multivariate consistent	Multivariate inconsistent	Up- / Downgrade	Final strength evidence
≤ 14 days between development of motor deficits to surgery	Low					-1: risk of bias	Very low

* Mollahoseini, 2011 identified the following "Site of primary cancer": lung, osteosarcoma, stomach, bladder, esophagus, pancreas vs. liver, gallbladder, unidentified vs. others vs. kidney, uterus vs. rectum vs. thyroid, breast, prostate, carcinoma

** Nemejc, 2014 identified the following "Site of primary cancer": breast, renal, myeloma, lung, prostate, colorectal, other

*** Hosono, 2005 defined "primary tumor with favorable prognosis" as those with more than 20 months median survival, which included myeloma, thyroid, kidney, breast, and prostate; and primary tumor with poor prognosis as those with less than 20 months median survival (lung, sarcoma, liver, colon, stomach, uterus, head and neck, bladder, thymus, pancreas, esophagus, and unknown)

**** Arrigo, 2011 defined "radiosensitive tumors" as breast, prostate, hematogenous, small cell lung, and germ cell; and all other tumors were classified as "radioresistant"

Abbreviations (alphabetical order): **ASIA**: American spinal injury association; **ECOG**: Eastern Cooperative Oncology Group; **KPS**: Karnofsky performance status; **NSCLC**: non-small cell lung cancer; **SSM**: symptomatic spinal metastasis; **vs.:** versus

doi:10.1371/journal.pone.0171507.t003

Table 4. Overall body of evidence for preoperative predictors of survival in surgical SSM patients from a single study.

Negative preoperative predictors	Baseline strength	Up- / Downgrade	Final strength of evidence
Breast cancer [48]			
Longer time interval from cancer diagnosis to surgery (year)	Low		Low
Admission to hospital via emergency room			
Poor/undifferentiated histologic grade			
Negative progesterone receptors			
Hepatocellular carcinoma[52]			
Serum albumin <37 g/L	Low	-1: risk of bias	Very low
Lactate dehydrogenase ≥ 200 U/L			
Lung cancer: NSCLC and SCLC[55]			
Presence of visceral metastasis	Low	-1: risk of bias	Very low
≤14 days between development of motor deficits due to SSM to surgery			
Non-ambulatory status			
≥ 60 years old patients[46]			
Original Tokuhashi score < 9 points	Low	-1: risk of bias	Very low
Rapid- or moderate-growing primary tumour Tomita grade			
Unknown site of primary tumor at the time of SSM surgery[47]			
Cervical spinal location	Low	<ul style="list-style-type: none"> • -1: risk of bias • -1: precision 	Very low
Presence of extraspinal disease at presentation			
Frankel A, B, C			

Abbreviations (alphabetical order): **NSCLC**: non-small cell lung cancer; **SCLC**: small cell lung cancer; **SSM**: symptomatic spinal metastasis

doi:10.1371/journal.pone.0171507.t004

constraints, the patient may be too unwell, undergoing other treatments, or they may prefer to be reviewed by local oncologists instead.

In addition, survival analyses are inherently complex, and our attempt to synthesize this group of 17 such studies was challenging due to considerable heterogeneity in patient samples and prognostic factors investigated. Furthermore, the design and reporting of the statistical analyses were problematic in many studies, leading to a moderately high risk of bias and difficulty interpreting the results. Since multivariate techniques applied to systematically collected data from a specific patient population may improve clinical prediction by identifying key prognostic factors[23, 60] and it is likely that various factors conjointly influence clinical outcomes such as survival or HRQoL, performing multivariate analysis was one of our inclusion criteria. Conducting multivariate analysis not only helps control for confounders, thus enhancing the confidence in the validity of the study results[61], but also provides an estimate of the actual effect size, offering both a clinical and statistical assessment of the impact of each factor on the outcome variable.[62]

Prognostic studies should be designed and conducted to minimize potential biases related to six domains.[35] (1) Study participants and sample: Data should be collected prospectively. Patients should be at a common point in the course of their disease. Patient sample assembly should include method, period, place of recruitment, and eligibility criteria. Patient sample should be adequately described for key characteristics. (2) Study attrition: The follow-up period should be long enough for the outcome(s) of interest to occur. The proportion of participants completing the study should be reported and adequate for the study design and analyses. If applicable, the reason(s) for loss to follow-up should be recorded. Account and measurement of (3) prognostic factors, (4) outcomes and (5) confounding factors: the definition and method of measurement of prognostic factors, outcomes and confounders should be

clearly described, valid, reliable and appropriate. An adequate proportion of the study sample should have complete data for prognostic factor, outcome and confounders, and if imputation is used for missing data, the method should be described and appropriate. (6) Analysis: The statistical analyses, including model selection and building, should be suitable for the study design, assumptions should be verified, and if applicable, adequate adjustment for confounding should be undertaken. Finally, all results should be adequately reported.[35, 63, 64]

The development of clinical prediction rules

While there is no well recognized CPR for HRQoL, the variable prognostic ability of current CPRs of survival[24–26] in this patient population may be related to the fact that patients who are deemed surgical candidates are fundamentally different, with overall greater life expectancy and fewer comorbidities, than patients selected for conservative or radiotherapy treatment alone. Selecting relevant predictors from a larger set of candidate predictors is one of the steps involved in the first phase of development of CPRs; these predictors are typically derived from best literature evidence. These CPRs could be of high clinical value by providing more accurate estimates of survival and HRQoL after surgery, helping not only to guide therapeutic decision-making during informed consent discussions, but also patients to form more realistic expectations relative to surgical outcomes.

Strengths and limitations

The systematic literature review was conducted in accordance with the PRISMA guidelines. We assessed the quality of the studies and evaluated the strength of the overall body of evidence for each preoperative predictor identified through our sensitive and rigorous literature review. However, this review aimed to identify predictors of a wide range of outcomes, combining the results of studies with substantial heterogeneity in the prognostic factors, outcome measures, and patient populations that were assessed, which may constitute a problem with internal validity. Furthermore, our *a priori* eligibility criteria were relatively narrow in their requirement and may have excluded studies that produced pertinent findings.

In predicting future outcomes by using patient data available at presentation, there will always be a degree of randomness or “chaos” in the system affecting clinical outcomes and survival.[65] Although we may improve prediction by establishing better methodology, there will always be random variability between studies and between patients, and there comes a point where studying preoperative patient variables too closely may not be helpful, due to the inherent variation that does not improve regardless of increasing sample size.

Conclusions

Life expectancy and HRQoL are cornerstones to clinical decision-making in surgical SSM patients. Based on the results of 17 pertinent studies, this systematic review found a low overall strength of evidence for seven preoperative predictors of survival and very low strength evidence for 39 additional predictors. Consequently, we have low confidence that the evidence reflects the true effect size of these predictors. Furthermore, no evidence was found for the prediction of neurologic, functional, and HRQoL outcomes. Further rigorously conducted prospective studies are needed to better understand what preoperative factors are prognostic of these various outcomes, for the purpose of surgical decision-making, development of CPRs, patient education and levering treatment expectations. Genetic analysis of tumor subtypes will also need to be included in future prediction models, since novel chemotherapies and immunotherapies are showing promising influence on survival and HRQoL.

Supporting information

S1 Checklist. PRISMA research checklist.

(DOC)

S1 Table. Complete search strategies from all seven databases.

(DOCX)

S2 Table. Different levels of evidence for predictive studies.

(DOCX)

S3 Table. Rating quality of the overall body of evidence.

(DOCX)

Acknowledgments

The authors thank Samantha Smith for collection of full text articles, Marina Eglesias and Melanie Anderson, information specialists at the University Health Network Health Sciences Libraries, for their invaluable help designing and performing our thorough literature search, and Dr. Pierre Côté for his insightful comments on an earlier version of this manuscript. No funding was received in direct support of this research but Dr. Fehlings is supported by the Gerry and Tootsie Halbert Chair in Neural Repair and Regeneration and the DeZwirek Family Foundation.

Author Contributions

Conceptualization: MGF AN.

Data curation: AN.

Formal analysis: AN AM AS DC.

Investigation: AN AM.

Methodology: MGF AN AM DC AS.

Project administration: MGF.

Resources: MGF.

Supervision: MGF.

Validation: MGF AM AS DC.

Visualization: AN.

Writing – original draft: AN.

Writing – review & editing: MGF AN AM AS DC.

References

1. Sciubba DM, Petteys RJ, Dekutoski MB, Fisher CG, Fehlings MG, Ondra SL, et al. Diagnosis and management of metastatic spine disease. *J Neurosurg Spine*. 2010; 13(1):94–108. Epub 2010/07/03. doi: [10.3171/2010.3.SPINE09202](https://doi.org/10.3171/2010.3.SPINE09202) PMID: [20594024](https://pubmed.ncbi.nlm.nih.gov/20594024/)
2. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. *Lancet Neurol*. 2008; 7(5):459–66. Epub 2008/04/19. doi: [10.1016/S1474-4422\(08\)70089-9](https://doi.org/10.1016/S1474-4422(08)70089-9) PMID: [18420159](https://pubmed.ncbi.nlm.nih.gov/18420159/)
3. Prasad D, Schiff D. Malignant spinal-cord compression. *Lancet Oncol*. 2005; 6(1):15–24. Epub 2005/01/05. doi: [10.1016/S1470-2045\(04\)01709-7](https://doi.org/10.1016/S1470-2045(04)01709-7) PMID: [15629272](https://pubmed.ncbi.nlm.nih.gov/15629272/)

4. Sciubba DM, Petteys RJ, Dekutoski MB, Fisher CG, Fehlings MG, Ondra SL, et al. Diagnosis and management of metastatic spine disease. A review. *J Neurosurg Spine*. 2010; 13(1):94–108. Epub 2010/07/03. doi: [10.3171/2010.3.SPINE09202](https://doi.org/10.3171/2010.3.SPINE09202) PMID: [20594024](https://pubmed.ncbi.nlm.nih.gov/20594024/)
5. National Cancer Institute. Cancer Statistics: U.S Department of Health and Human Services—National Institutes of Health; Last updated: March 14, 2016 [March 18th, 2016]. <http://www.cancer.gov/about-cancer/what-is-cancer/statistics>.
6. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet*. 2005; 366(9486):643–8. Epub 2005/08/23. doi: [10.1016/S0140-6736\(05\)66954-1](https://doi.org/10.1016/S0140-6736(05)66954-1) PMID: [16112300](https://pubmed.ncbi.nlm.nih.gov/16112300/)
7. L'Esperance S, Vincent F, Gaudreault M, Ouellet JA, Li M, Tosikyan A, et al. Treatment of metastatic spinal cord compression: cepto review and clinical recommendations. *Curr Oncol*. 2012; 19(6):e478–90. Epub 2013/01/10. doi: [10.3747/co.19.1128](https://doi.org/10.3747/co.19.1128) PMID: [23300371](https://pubmed.ncbi.nlm.nih.gov/23300371/)
8. National Collaborating Centre for Cancer (UK). Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression. Cardiff (UK)2008 Nov. (NICE Clinical Guidelines, No. 75.) [November 22, 2013]. <http://www.ncbi.nlm.nih.gov/books/NBK55007/>.
9. Fehlings MG, Nater A, Tetreault L, Kopjar B, Arnold P, Dekutoski M, et al. Survival and Clinical Outcomes in Surgically Treated Patients With Metastatic Epidural Spinal Cord Compression: Results of the Prospective Multicenter AOSpine Study. *J Clin Oncol*. 2016; 34(3):268–76. Epub 2015/11/26. doi: [10.1200/JCO.2015.61.9338](https://doi.org/10.1200/JCO.2015.61.9338) PMID: [26598751](https://pubmed.ncbi.nlm.nih.gov/26598751/)
10. Vigano A, Dorgan M, Bruera E, Suarez-Almazor ME. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. *Cancer*. 1999; 86(1):170–6. Epub 1999/07/03. PMID: [10391577](https://pubmed.ncbi.nlm.nih.gov/10391577/)
11. Chow E, Harth T, Hruba G, Finkelstein J, Wu J, Danjoux C. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. *Clin Oncol (R Coll Radiol)*. 2001; 13(3):209–18. Epub 2001/08/31.
12. Clement-Duchene C, Carnin C, Guillemin F, Martinet Y. How accurate are physicians in the prediction of patient survival in advanced lung cancer? *Oncologist*. 2010; 15(7):782–9. Epub 2010/06/19. doi: [10.1634/theoncologist.2009-0149](https://doi.org/10.1634/theoncologist.2009-0149) PMID: [20558582](https://pubmed.ncbi.nlm.nih.gov/20558582/)
13. Holmebakk T, Solbakken A, Mala T, Nesbakken A. Clinical prediction of survival by surgeons for patients with incurable abdominal malignancy. *Eur J Surg Oncol*. 2011; 37(7):571–5. Epub 2011/03/30. doi: [10.1016/j.ejso.2011.02.009](https://doi.org/10.1016/j.ejso.2011.02.009) PMID: [21444178](https://pubmed.ncbi.nlm.nih.gov/21444178/)
14. Wai EK, Finkelstein JA, Tangente RP, Holden L, Chow E, Ford M, et al. Quality of life in surgical treatment of metastatic spine disease. *Spine (Phila Pa 1976)*. 2003; 28(5):508–12. Epub 2003/03/05.
15. Falicov A, Fisher CG, Sparkes J, Boyd MC, Wing PC, Dvorak MF. Impact of surgical intervention on quality of life in patients with spinal metastases. *Spine (Phila Pa 1976)*. 2006; 31(24):2849–56. Epub 2006/11/17.
16. Jansson KA, Bauer HC. Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases. *Eur Spine J*. 2006; 15(2):196–202. Epub 2005/03/04. doi: [10.1007/s00586-004-0870-6](https://doi.org/10.1007/s00586-004-0870-6) PMID: [15744540](https://pubmed.ncbi.nlm.nih.gov/15744540/)
17. Ibrahim A, Crockard A, Antonietti P, Boriani S, Bunger C, Gasbarrini A, et al. Does spinal surgery improve the quality of life for those with extradural (spinal) osseous metastases? An international multicenter prospective observational study of 223 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2007. *J Neurosurg Spine*. 2008; 8(3):271–8. Epub 2008/03/04. doi: [10.3171/SPI/2008/8/3/271](https://doi.org/10.3171/SPI/2008/8/3/271) PMID: [18312079](https://pubmed.ncbi.nlm.nih.gov/18312079/)
18. Fujibayashi S, Neo M, Miyaki K, Nakayama T, Nakamura T. The value of palliative surgery for metastatic spinal disease: satisfaction of patients and their families. *Spine J*. 2010; 10(1):42–9. <http://dx.doi.org/10.1016/j.spinee.2009.06.016>. PMID: [19665939](https://pubmed.ncbi.nlm.nih.gov/19665939/)
19. Pointillart V, Vital J-M, Salmi R, Diallo A, Quan GM. Survival prognostic factors and clinical outcomes in patients with spinal metastases. *J Cancer Res Clin Oncol*. 2011; 137(5):849–56. <http://dx.doi.org/10.1007/s00432-010-0946-0>. PMID: [20820803](https://pubmed.ncbi.nlm.nih.gov/20820803/)
20. Quan GM, Vital JM, Aurouer N, Obeid I, Palussiere J, Diallo A, et al. Surgery improves pain, function and quality of life in patients with spinal metastases: a prospective study on 118 patients. *Eur Spine J*. 2011; 20(11):1970–8. Epub 2011/06/28. doi: [10.1007/s00586-011-1867-6](https://doi.org/10.1007/s00586-011-1867-6) PMID: [21706361](https://pubmed.ncbi.nlm.nih.gov/21706361/)
21. Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. *Pharmacoeconomics*. 2014; 32(2):173–91. Epub 2014/01/18. doi: [10.1007/s40273-013-0121-y](https://doi.org/10.1007/s40273-013-0121-y) PMID: [24435407](https://pubmed.ncbi.nlm.nih.gov/24435407/)

22. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. *PLoS Med.* 2013; 10(2):e1001381. Epub 2013/02/09. doi: [10.1371/journal.pmed.1001381](https://doi.org/10.1371/journal.pmed.1001381) PMID: [23393430](https://pubmed.ncbi.nlm.nih.gov/23393430/)
23. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? *BMJ.* 2009; 338:b375. Epub 2009/02/25. doi: [10.1136/bmj.b375](https://doi.org/10.1136/bmj.b375) PMID: [19237405](https://pubmed.ncbi.nlm.nih.gov/19237405/)
24. Leithner A, Radl R, Gruber G, Hochegger M, Leithner K, Welkerling H, et al. Predictive value of seven preoperative prognostic scoring systems for spinal metastases. *Eur Spine J.* 2008; 17(11):1488–95. <http://dx.doi.org/10.1007/s00586-008-0763-1>. PMID: [18787846](https://pubmed.ncbi.nlm.nih.gov/18787846/)
25. Bollen L, Wibmer C, Van der Linden YM, Pondaag W, Fiocco M, Peul WC, et al. Predictive Value of Six Prognostic Scoring Systems for Spinal Bone Metastases: An Analysis Based on 1379 Patients. *Spine (Phila Pa 1976).* 2016; 41(3):E155–62. Epub 2016/02/13.
26. Wibmer C, Leithner A, Hofmann G, Clar H, Kapitan M, Berghold A, et al. Survival analysis of 254 patients after manifestation of spinal metastases: evaluation of seven preoperative scoring systems. *Spine.* 2011; 36(23):1977–86. <http://dx.doi.org/10.1097/BRS.0b013e3182011f84>. PMID: [21304424](https://pubmed.ncbi.nlm.nih.gov/21304424/)
27. Bartels RH, Feuth T, van der Maazen R, Verbeek AL, Kappelle AC, Andre Grotenhuis J, et al. Development of a model with which to predict the life expectancy of patients with spinal epidural metastasis. *Cancer.* 2007; 110(9):2042–9. Epub 2007/09/14. doi: [10.1002/cncr.23002](https://doi.org/10.1002/cncr.23002) PMID: [17853394](https://pubmed.ncbi.nlm.nih.gov/17853394/)
28. Bartels RH, de Ruiter G, Feuth T, Arts MP. Prediction of life expectancy in patients with spinal epidural metastasis. *Neuro Oncol.* 2016; 18(1):114–8. Epub 2015/08/09. doi: [10.1093/neuonc/nov149](https://doi.org/10.1093/neuonc/nov149) PMID: [26254478](https://pubmed.ncbi.nlm.nih.gov/26254478/)
29. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009; 6(7):e1000097. Epub 2009/07/22. doi: [10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097) PMID: [19621072](https://pubmed.ncbi.nlm.nih.gov/19621072/)
30. PROSPERO—International Prospective Register of Systematic Reviews. <http://www.crd.york.ac.uk/PROSPERO/>.
31. R.R. Bowker Company, and Serials Solutions. Ulrichsweb: Global Serials Directory New Providence; NJ: R.R. Bowker; 2016 [January 21st, 2016]. <http://ulrichsweb.serialssolutions.com>.
32. Skelly AC, Hashimoto RE, Norvell DC, Dettori JR, Fischer DJ, Wilson JR, et al. Cervical spondylotic myelopathy: methodological approaches to evaluate the literature and establish best evidence. *Spine (Phila Pa 1976).* 2013; 38(22 Suppl 1):S9–18. Epub 2013/09/13.
33. Dettori JR, Norvell DC, Skelly AC. Methodology Checklist and Risk of Bias Definitions for Prognostic Studies: Spectrum Research Standard Operating Procedures for Systematic Review: Tacoma, WA: Spectrum Research, Inc. Evidence-Based Practice Division; 2013.
34. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol.* 2011; 64(4):401–6. Epub 2011/01/07. doi: [10.1016/j.jclinepi.2010.07.015](https://doi.org/10.1016/j.jclinepi.2010.07.015) PMID: [21208779](https://pubmed.ncbi.nlm.nih.gov/21208779/)
35. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. *Ann Intern Med.* 2006; 144(6):427–37. Epub 2006/03/22. PMID: [16549855](https://pubmed.ncbi.nlm.nih.gov/16549855/)
36. North RB, LaRocca VR, Schwartz J, North CA, Zahurak M, Davis RF, et al. Surgical management of spinal metastases: analysis of prognostic factors during a 10-year experience. *J Neurosurg Spine.* 2005; 2(5):564–73. doi: [10.3171/spi.2005.2.5.0564](https://doi.org/10.3171/spi.2005.2.5.0564) PMID: [15945430](https://pubmed.ncbi.nlm.nih.gov/15945430/)
37. Chaichana KL, Woodworth GF, Sciubba DM, McGirt MJ, Witham TJ, Bydon A, et al. Predictors of ambulatory function after decompressive surgery for metastatic epidural spinal cord compression. *Neurosurgery.* 2008; 62(3):683–92; discussion -92. <http://dx.doi.org/10.1227/01.neu.0000317317.33365.15>. PMID: [18425015](https://pubmed.ncbi.nlm.nih.gov/18425015/)
38. Kim CH, Chung CK, Jahng T-A, Kim HJ. Resumption of ambulatory status after surgery for nonambulatory patients with epidural spinal metastasis. *Spine J.* 2011; 11(11):1015–23. <http://dx.doi.org/10.1016/j.spinee.2011.09.007>. PMID: [22000724](https://pubmed.ncbi.nlm.nih.gov/22000724/)
39. Moon KY, Chung CK, Jahng T-A, Kim HJ, Kim CH. Postoperative survival and ambulatory outcome in metastatic spinal tumors: prognostic factor analysis. *J.* 2011; 50(3):216–23. <http://dx.doi.org/10.3340/jkns.2011.50.3.216>.
40. Park JH, Rhim SC, Jeon SR. Efficacy of decompression and fixation for metastatic spinal cord compression: analysis of factors prognostic for survival and postoperative ambulation. *J.* 2011; 50(5):434–40. <http://dx.doi.org/10.3340/jkns.2011.50.5.434>.
41. Lei M, Liu Y, Tang C, Yang S, Liu S, Zhou S. Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer. *BMC Cancer.* 2015; 15:853. Epub 2015/11/07. doi: [10.1186/s12885-015-1852-2](https://doi.org/10.1186/s12885-015-1852-2) PMID: [26541141](https://pubmed.ncbi.nlm.nih.gov/26541141/)
42. Choi D, Fox Z, Albert T, Arts M, Balabaud L, Bunger C, et al. Prediction of Quality of Life and Survival After Surgery for Symptomatic Spinal Metastases: A Multicenter Cohort Study to Determine Suitability

- for Surgical Treatment. *Neurosurgery*. 2015; 77(5):698–708; discussion Epub 2015/07/24. doi: [10.1227/NEU.0000000000000907](https://doi.org/10.1227/NEU.0000000000000907) PMID: [26204361](https://pubmed.ncbi.nlm.nih.gov/26204361/)
43. Finkelstein JA, Zaveri G, Wai E, Vidmar M, Kreder H, Chow E. A population-based study of surgery for spinal metastases. Survival rates and complications. *J Bone Joint Surg Br*. 2003; 85(7):1045–50. Epub 2003/10/01. PMID: [14516044](https://pubmed.ncbi.nlm.nih.gov/14516044/)
 44. Hosono N, Ueda T, Tamura D, Aoki Y, Yoshikawa H. Prognostic relevance of clinical symptoms in patients with spinal metastases. *Clin Orthop Relat Res*. 2005;(436):196–201. Epub 2005/07/05. PMID: [15995441](https://pubmed.ncbi.nlm.nih.gov/15995441/)
 45. Nemelc RM, Stadhouders A, van Royen BJ, Jiya TU. The outcome and survival of palliative surgery in thoraco-lumbar spinal metastases: contemporary retrospective cohort study. *Eur Spine J*. 2014; 23(11):2272–8. Epub 2014/03/25. doi: [10.1007/s00586-014-3268-0](https://doi.org/10.1007/s00586-014-3268-0) PMID: [24659388](https://pubmed.ncbi.nlm.nih.gov/24659388/)
 46. Liang T, Wan Y, Zou X, Peng X, Liu S. Is surgery for spine metastasis reasonable in patients older than 60 years? *Clin Orthop Relat Res*. 2013; 471(2):628–39. Epub 2012/11/28. doi: [10.1007/s11999-012-2699-3](https://doi.org/10.1007/s11999-012-2699-3) PMID: [23179121](https://pubmed.ncbi.nlm.nih.gov/23179121/)
 47. Aizenberg MR, Fox BD, Suki D, McCutcheon IE, Rao G, Rhines LD. Surgical management of unknown primary tumors metastatic to the spine. *J Neurosurg Spine*. 2012; 16(1):86–92. Epub 2011/10/11. doi: [10.3171/2011.9.SPINE11422](https://doi.org/10.3171/2011.9.SPINE11422) PMID: [21981272](https://pubmed.ncbi.nlm.nih.gov/21981272/)
 48. Cahill KS, Chi JH, Day AL, Claus EB. Trends in survival after surgery for breast cancer metastatic to the brain and spinal column in medicare patients: a population-based analysis. *Neurosurgery*. 2011; 68(3):705–13; discussion 13. <http://dx.doi.org/10.1227/NEU.0b013e31820773b2>. PMID: [21164378](https://pubmed.ncbi.nlm.nih.gov/21164378/)
 49. Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, et al. Surgical management of prostate cancer metastatic to the spine. *J Neurosurg Spine*. 2009; 10(5):414–22. <http://dx.doi.org/10.3171/2009.1.SPINE08509>. PMID: [19442002](https://pubmed.ncbi.nlm.nih.gov/19442002/)
 50. Arrigo RT, Kalanithi P, Cheng I, Alamin T, Carragee EJ, Mindea SA, et al. Predictors of survival after surgical treatment of spinal metastasis. *Neurosurgery*. 2011; 68(3):674–81; discussion 81. Epub 2011/02/12. doi: [10.1227/NEU.0b013e318207780c](https://doi.org/10.1227/NEU.0b013e318207780c) PMID: [21311295](https://pubmed.ncbi.nlm.nih.gov/21311295/)
 51. Chen YJ, Chen HT, Hsu HC. Preoperative palsy score has no significant association with survival in non-small-cell lung cancer patients with spinal metastases who undergo spinal surgery. *J Orthop Surg Res*. 2015; 10:149. Epub 2015/09/19. doi: [10.1186/s13018-015-0291-8](https://doi.org/10.1186/s13018-015-0291-8) PMID: [26381378](https://pubmed.ncbi.nlm.nih.gov/26381378/)
 52. Chen H, Xiao J, Yang X, Zhang F, Yuan W. Preoperative scoring systems and prognostic factors for patients with spinal metastases from hepatocellular carcinoma. *Spine*. 2010; 35(23):E1339–46. <http://dx.doi.org/10.1097/BRS.0b013e3181e574f5>. PMID: [20938387](https://pubmed.ncbi.nlm.nih.gov/20938387/)
 53. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. *Spine (Phila Pa 1976)*. 2001; 26(3):298–306. Epub 2001/02/27.
 54. Crnalic S, Lofvenberg R, Bergh A, Widmark A, Hildingsson C. Predicting survival for surgery of metastatic spinal cord compression in prostate cancer: a new score. *Spine*. 2012; 37(26):2168–76. <http://dx.doi.org/10.1097/BRS.0b013e31826011bc>. PMID: [22648028](https://pubmed.ncbi.nlm.nih.gov/22648028/)
 55. Lei M, Liu Y, Yan L, Tang C, Yang S, Liu S. A validated preoperative score predicting survival and functional outcome in lung cancer patients operated with posterior decompression and stabilization for metastatic spinal cord compression. *Eur Spine J*. 2015. Epub 2015/10/29.
 56. Mollahoseini R, Farhan F, Khajoo A, Jouibari MA, Gholipour F. Is Tokuhashi score suitable for evaluation of life expectancy before surgery in Iranian patients with spinal metastases? *J Res Med Sci*. 2011; 16(9):1183–8. Epub 2012/09/14. PMID: [22973387](https://pubmed.ncbi.nlm.nih.gov/22973387/)
 57. Bollen L, De Ruiter GCW, Pondaag W, Arts MP, Fiocco M, Hazen TJJ, et al. Risk factors for survival of 106 surgically treated patients with symptomatic spinal epidural metastases. *Eur Spine J*. 2013; 22(6):1408–16. <http://dx.doi.org/10.1007/s00586-013-2726-4>. PMID: [23455954](https://pubmed.ncbi.nlm.nih.gov/23455954/)
 58. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987; 40(5):373–83. Epub 1987/01/01. PMID: [3558716](https://pubmed.ncbi.nlm.nih.gov/3558716/)
 59. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. *Spine*. 2001; 26(3):298–306. PMID: [11224867](https://pubmed.ncbi.nlm.nih.gov/11224867/)
 60. Randolph AG, Guyatt GH, Calvin JE, Doig G, Richardson WS. Understanding articles describing clinical prediction tools. *Evidence Based Medicine in Critical Care Group. Crit Care Med*. 1998; 26(9):1603–12. Epub 1998/09/29. PMID: [9751601](https://pubmed.ncbi.nlm.nih.gov/9751601/)
 61. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. *Br J Cancer*. 2003; 89(2):232–8. Epub 2003/07/17. doi: [10.1038/sj.bjc.6601118](https://doi.org/10.1038/sj.bjc.6601118) PMID: [12865907](https://pubmed.ncbi.nlm.nih.gov/12865907/)
 62. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis—an introduction to concepts and methods. *Br J Cancer*. 2003; 89(3):431–6. Epub 2003/07/31. doi: [10.1038/sj.bjc.6601119](https://doi.org/10.1038/sj.bjc.6601119) PMID: [12888808](https://pubmed.ncbi.nlm.nih.gov/12888808/)

63. Altman DG. Systematic reviews of evaluations of prognostic variables. *Bmj*. 2001; 323(7306):224–8. Epub 2001/07/28. PMID: [11473921](#)
64. Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. *Adv Otorhinolaryngol*. 2005; 62:184–200. Epub 2004/12/21. doi: [10.1159/000082508](#) PMID: [15608428](#)
65. Lorenz EN. Atmospheric predictability as revealed by naturally occurring analogues. *Journal of the Atmospheric Sciences*. 1969; 24(4):636–46.